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Abstract 
Tuberculosis (TB) still ranks among the most lethal infectious diseases in the world. The 
traditional distinction between active tuberculosis and latent tuberculosis infection (LTBI) is 
changing; at the moment, tuberculosis infection is described as a continuum with different 
stages of infection. The development of TB prevention, treatment and diagnostics is 
hampered by the diverse pathogenesis of the disease and the ability of the bacteria to fight 
host defence mechanisms. Traditional culture methods are slow and staining methods not 
sufficiently sensitive. Nucleic acid amplification techniques (NAAT) tend to be costly and in 
some cases lack sensitivity. New methods are needed for rapid and inexpensive detection of 
active disease and to distinguish between stages of infection in cases where the patient 
presents with symptoms compatible with active TB and with a positive Interferon Gamma 
Release Assay (IGRA) result, but bacteriological confirmation is not yet available. In addition, 
methods are needed that enable us to predict the activation of infection or monitor the 
effects of treatment. 
The aim of this thesis was to investigate: a) the possible diagnostic use of heparin-binding 
haemagglutinin (HBHA), a surface protein of M. tuberculosis, in distinguishing between 
stages of infection in a vaccinated population; b) the effect of sample concentration on the 
properties of Clearview® TB ELISA, a urine antigen test measuring lipoarabinomannan (LAM), 
a M. tuberculosis glycolipid, in the diagnosis of active TB; c) the suitability of granzyme B 
(GrB), perforin (Prf), and interferon-gamma (IFN-γ)-producing and CD107a-degranulation 
factor-expressing cytotoxic T lymphocytes (CTLs) for differentiating between stages of 
infection; d) the suitability of IFN-γ, interleukin (IL) -17, IL-4, IL-4δ2 and Forkhead box P3 
(FoxP3) mRNA expression levels for differentiation between stages of infection.  
The results showed that HBHA-specific cells producing IFN-γ were also found in the 
circulation of healthy subjects who had been given the Bacillus Calmette-Guérin vaccine. In 
view of this, use of the HBHA antigen for diagnostic purposes does not look promising in 
countries where a widespread vaccination programme has taken place. No differences were 
found in the numbers or phenotypic properties of CTLs between persons with active TB and 
those with LTBI, which is why they are not suited for the differential diagnosis of infection 
stages.  
Functional antigen-specific CTLs were found in the circulation of persons who had been 
treated for TB. This most significant finding of this thesis demonstrates that the T cell 
memory generated by active TB maintains functionally active CTL populations decades after 
infection and despite adequate treatment with rifampicin.  
Although no statistically significant differences were found between patients with active TB 
and LTBI in the quantitative detection of IFN-γ, IL-17, or IL-4 mRNA from cells stimulated with 
purified protein derivative (PPD), this approach revealed a trend towards discrimination. The 
usefulness of combined quantitative IFN-γ, IL-17, and IL-4 mRNA expression for the 
differential diagnosis of active TB and LTBI should be retested with a larger sample size 
enrolling more homogenous patients in the LTBI group.  
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The findings indicating that LAM may be detected with moderate sensitivity (57%) in the 
urine samples of TB patients show the greatest promise from a diagnostic point of view. The 
100-fold concentration of urine used in this study improved the sensitivity of the Clearview® 
TB ELISA test from 7% to 57%, although specificity was decreased somewhat from 98% to 
89%. Based on the results, demonstrating the presence of LAM in urine samples may be 
considered a potential diagnostic tool for detecting active TB. The method does require 
further development, however.  
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Tiivistelmä 
Tuberkuloosi (TB) kuuluu vielä nykyisinkin tappavimpiin tartuntatauteihin maailmassa. 
Perinteinen jako aktiiviseen ja latenttiin tuberkuloosiin (LTBI) on muuttumassa; nyttemmin 
tuberkuloosi-infektio kuvataan vaihteleva-asteisena jatkumona. Patogeneesin 
monimuotoisuus ja bakteerin kyky torjua isännän puolustusmekanismeja hankaloittavat 
ennaltaehkäisyn, hoitomenetelmien ja diagnostiikan kehitystä. Perinteisen TB-viljelyn 
heikkoutena on hitaus, ja värjäys tiedetään epäherkäksi.  Geenimonistusmenetelmien 
käyttöä puolestaan rajoittaa hintavuus eikä niiden herkkyys aina riitä. Uusia keinoja kaivataan 
taudin nopeaan ja edulliseen osoittamiseen sekä infektion asteiden erotteluun esimerkiksi 
tilanteissa, joissa potilaalla on aktiiviseen tuberkuloosiin viittaavia oireita ja positiivinen 
gammainterferoni (IGRA) -tulos, mutta bakteriologinen varmistus puuttuu. Lisäksi tarvitaan 
menetelmiä, joilla voidaan ennustaa infektion aktivoitumista tai seurata hoidon vaikutuksia. 
Tässä väitöskirjatyössä selvitettiin: a) M. tuberculosis -pintaproteiinin, heparin-binding 
hemagglutiniinin (HBHA), diagnostista käyttömahdollisuutta eroteltaessa rokotetussa 
väestössä infektion eri asteita; b) konsentroinnin vaikutusta M. tuberculosis -bakteerin 
glykolopidiä, lipoarabinomannaania (LAM), mittaavan virtsan antigeenitestin, Clearview® TB 
ELISA:n, ominaisuuksiin aktiivi-TB-diagnostiikassa; c) granzyme B:tä (GrB), perforiiniä (Prf) ja 
gammainterferonia (IFN-γ) tuottavien sekä CD107a-degranulaatiofaktoria ekspressoivien 
sytotoksisten T-lymfosyyttien soveltuvuutta infektion asteiden erotteluun; d) IFN-γ, 
interleukiini (IL) -17, IL-4, IL-4δ2 ja Forkhead box P3 (FoxP3) -mRNA-ekspressiotasojen 
toimivuutta infektion asteiden erottelussa.  
Tutkimuksessa löydettiin myös terveiden Bacillus Calmette-Guérin (BCG) -rokotteen 
saaneiden verestä HBHA-spesifisiä, IFN-γ:aa tuottavia soluja. HBHA-antigeenia ei siis voitane 
hyödyntää diagnostiikassa maissa, joissa rokotusohjelmaan on kuulunut lasten BCG-rokotus. 
Aktiivi-TB- ja LTBI-ryhmien välillä ei havaittu määrällisiä eikä fenotyyppisiä eroavuuksia 
sytotoksissa T-lymfosyyteissä, joten ne eivät sovellu käytettäviksi infektion asteiden 
erotusdiagnostiikassa.  
Toiminnallisia antigeenispesifisiä sytotoksisia T-lymfosyyttejä havaittiin myös 
tuberkuloosihoidon saaneiden verinäytteissä. Tämä on väitöskirjan arvokkain löydös. Se 
osoittaa, että aktiivi-TB:n aikaansaama T-solumuisti ylläpitää toiminnallisesti aktiivista 
sytotoksisten T-solujen populaatiota vuosikymmeniä, asianmukaisesta rifampisiinihoidosta 
huolimatta.  
Vaikka IFN-γ-, IL-17- ja IL-4 mRNA -ekspressiotasoissa ei esiintynyt tilastollisesti merkitseviä 
eroja purified protein derivative (PPD) -stimuloiduissa soluissa, aktiivi-TB- ja LTBI-ryhmien 
välillä oli nähtävissä erotteleva suuntaus. IFN-γ-, IL-17- ja IL-4 mRNA- ekspression 
hyödyntämistä aktiivi-TB:n erottamiseksi LTBI:stä tulisikin tulevaisuudessa testata 
suuremmalla ja yhtenäisemmällä LTBI-aineistolla.  
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Diagnostiikan kannalta lupaavampia ovat tulokset, joiden perusteella LAM voidaan osoittaa 
tuberkuloosipotilaiden virtsanäytteestä kohtalaisella herkkyydellä (57%). Tässä työssä 
käytetty virtsan satakertainen konsentrointi paransi Clearview® TB ELISA -testin herkkyyttä 
7%:sta 57%:iin; spesifisyys tosin samalla heikkeni 98%:sta 89%:iin. LAM:n osoittamista 
virtsanäytteestä voidaan mahdollisesti hyödyntää aktiivi-TB:n diagnosoinnissa, tosin 
menetelmä vaatisi vielä kehittämistä.  
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1. REVIEW OF THE LITERATURE  
1.1. History and epidemiology of tuberculosis 
The disease tuberculosis (TB) has been known for millennia, and the causative agent, 
Mycobacterium tuberculosis (M. tuberculosis), is thought to have existed for 150 000 years 
[1]. M. tuberculosis has been found by PCR sequencing from a 17 000-year-old bone of a 
bison in Wyoming, USA [2]. In humans, M. tuberculosis has been detected from the bone of 
Neolithic infant and a woman in a 9000-year-old settlement in the Eastern Mediterranean 
[3]. The characteristic lesion of the disease, the tubercle, was first described by Laennec in 
1819, and the disease was named tuberculosis by Johann Lukas Schönlein in 1834. A few 
decades later, Jean-Antoine Villemin demonstrated the transmissibility of the infection. After 
centuries of speculation, in 1882, the German scientist Robert Koch reported the isolation of 
tubercle bacillus, the causative agent of tuberculosis. One year later, the bacillus was named 
M. tuberculosis. [1, 4] 
Worldwide, TB remains a major health problem. It has been ranked as the second leading 
cause of death by an infectious disease after the human immune deficiency virus (HIV) 
infection. Almost 9 million new TB cases and 1.3 million TB deaths (including 300 000 HIV-
associated cases) were estimated in 2012. Most of the cases occurred in Asia (58%) and 
Africa (27%), with fewer cases in the Eastern Mediterranean region (8%), the European 
region (4%) and the region of the Americas (3%). Multidrug-resistant (MDR), extensively 
drug-resistant (XDR), and most recently, M. tuberculosis strains that are resistant to all anti-
tuberculosis drugs have emerged over the past two decades. In 2012, there were 450 000 
estimated MDR-TB cases among diagnosed pulmonary TB patients, from which the highest 
incidences were in Eastern European and Central Asian countries. [5] 
In Finland, there were almost 9000 TB deaths per year in 1930, and TB was a dreaded 
national disease. The incidence and death rates began to decline in the 1940s due to the 
development of the first anti-tuberculous drugs and the establishment of national 
preventative programs with sanatorium activity. [6] In 2012, only 261 new TB cases and 3 
MDR-TB cases were recorded in Finland [5]. However, increasing immigration and high 
incidence rates in neighboring countries, as well as the reactivation risk in persons infected in 
the 1940s and 1950s, are causes for concern at present.   
Currently, the prevention, control, vaccination, diagnostics and treatment of TB are 
accurately monitored worldwide by the surveillance programs of WHO, the Centre for 
Disease Control and Prevention (CDC), and the European Centre for Disease Control and 
Prevention (ECDC). Although the incidence rates have decreased worldwide during the last 
decade, the challenges in tuberculosis control remain. 
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1.2. Mycobacterium tuberculosis 
1.2.1. Taxonomy and characteristics 
Mycobacteria are acid-fast, aerobic, non-motile, non-encapsulated and non-spore-forming 
bacilli with a high DNA GC content. The genus Mycobacterium is the only member of the 
Mycobacteriacae family, but forms a uniform group with a range of other mycolic acid-
containing genera, namely Gordonia, Tsukamurella, Nocardia, and Rhodococcus. M. 
tuberculosis belongs to the M. tuberculosis complex, together with the species M. bovis, M. 
africanum, M. microti, M. canettii, and M. pinnipedii, forming a tight and discrete group with 
>95% DNA-DNA homology. [7] The complete genome of the first sequenced laboratory strain 
of M. tuberculosis, H37Rv, consists of 4.4 x 106 base pairs and contains approximately 4000 
genes, including regions that are deleted in other members of the complex [8].  
M. tuberculosis is an obligate intracellular pathogen, which most successfully infects tissues 
with a high oxygen content, such as the lungs, but can infect almost any organ of the host. It 
principally infects humans, but can also infect several other animal species. M. tuberculosis 
divides extremely slowly (15–20 hours) compared to other bacteria and has the ability to 
persist in a latent state. Mycobacteria are highly resistant to desiccation, alkaline conditions, 
chemical disinfectants, and therapeutic agents. This resistance is related to the unusual 
structure and low permeability of the mycobacterial cell wall. [7, 9] M. tuberculosis lacks such 
virulence factors as toxins. However, important virulence determinants have been found, for 
example, in the categories of cell envelope proteins, lipid and fatty acid metabolism, 
proteases, gene expression regulators, and the proteins inhibiting antimicrobial response of 
macrophages, such as phagolysosome fusion and the production of reactive oxygen and 
nitrogen. [10]  
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1.2.2. Structure of the cell envelope 
The peptidoglycan of mycobacteria contains a unique meso-diaminopimelic acid and an N-
glycosylated muramic acid residue, in contrast to the N-acetylation of other bacteria. 
Together with its unique polysaccharide, arabinogalactan, supplemented by mycolic acids, 
peptidoglycan composes the core of the cell wall, the mycolylarabinogalactan-peptidoglycan 
(mAGP) complex. Phosphatidylinositolmannosides (PIMs) are the main plasma membrane 
components and form the lipid anchor of lipoarabinomannan (LAM) and lipomannan, which 
belong to the upper segment of the cell wall together with free lipids and proteins (Figure 1). 
[11, 12]  
 
 
 
 
Figure 1. The mycobacterial cell wall. Reprinted with permission from Oxford University Press: Glycobiology 
[12], copyright 2013. 
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1.3. Tuberculosis 
TB is an airborne infectious disease caused by mycobacteria, usually by M. tuberculosis. In 
most cases, it occurs in the lungs of the host. Infection outside the lung is called 
extrapulmonary TB (EPTB). The transmission of infection ensues when a susceptible person 
inhales M. tuberculosis-containing particles, or droplet nuclei, generated for example by 
coughing or sneezing of a patient with pulmonary tuberculosis (PTB) [7]. A person inhaling M. 
tuberculosis aerosols has a 5–10% risk of developing active TB, a rapidly progressive disease 
that can be diagnosed with microbiological, radiological, or histological findings. The risk of 
disease activation is the highest within the first few years after transmission. Most 
immunocompetent persons develop an effective immune response and succeed in 
eliminating M. tuberculosis, or remain asymptomatic and non-infectious, having a so-called 
latent tuberculosis infection (LTBI). The diagnosis of LTBI is based on the known history of TB 
exposure and the measurement of a host's immune response to M. tuberculosis antigens 
using either tuberculin skin test (TST) or interferon-γ (IFN-γ) release assay (IGRA). [9, 13] 
Nowadays, the traditional dichotomy of active TB and LTBI is changing to a continuum of 
infection, including a wide spectrum of infection stages. Presently, LTBI is defined to range 
from the completely cleared infection to the stage where replicating bacteria without clinical 
symptoms are present. Meanwhile, active TB can represent diverse presentations from a 
subclinical infection to a clinical disease with an extensive load of replicating bacteria. [13]  
1.3.1. Pathogenesis  
The interaction between M. tuberculosis and its host is complex and the pathogenesis and 
immunological processes are not yet well understood. For example, regulation of the 
transition from primary growth to persistence, further reactivation of LTBI, bacterial 
determinants required for persistence, and the metabolic state of M. tuberculosis during 
latency are currently under investigation. [14]  
1.3.1.1. Infection initiation and innate immunity 
After M. tuberculosis is inhaled in respiratory droplets, it is ingested by airway antigen-
presenting cells, such as monocyte-derived macrophages and dendritic cells (DCs) [15]. The 
recognition and binding of cell wall components, such as mannose-capped LAM (ManLAM) 
and PIMs, as well as bacterial uptake, are executed by numerous receptors, including C-type 
lectin receptors, complement receptors and scavenger receptors. Toll-like receptors and 
nucleotide-binding oligomerization receptors are important for the induction of synthesis of 
pro-inflammatory cytokines. [16] Upon M. tuberculosis recognition, pro-inflammatory 
cytokines, such as interleukin (IL)-6, IL-21, IL-1β, and IL-12p40, are expressed by phagocytic 
cells mentioned above [17]. Infected phagocytes migrate across the alveolar epithelium into 
the lung tissue, where granuloma formation is initiated by macrophages [18]. Infected 
macrophages express vimentin, which is recognized by the NKp46 receptor of natural killer 
(NK) cells. Activated NK cells lyse M. tuberculosis-infected macrophages with a help of 
antimicrobial granulysin. [19] In early mycobacterial infection in mice, γδ T cells have been 
reported to be a major source of proinflammatory IL-17. These cells get activated antigen-
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independently by IL-23. IL-17 has a role in the initiation of granuloma formation and early 
neutrophil recruitment. [17] Neutrophils are rapidly recruited to the infection site after 
infection initiation. They directly internalize mycobacteria using pattern recognition 
receptors (PRRs) or by opsonization and lyse them with mechanisms such as human 
neutrophil proteins (HNPs), stored in azurophilic granules. Neutrophils also participate in the 
recruitment of macrophages. [20] 
M. tuberculosis is transported by DCs to the local draining lymph nodes and antigens are 
presented to naïve T cells. CD8+ and CD4+ T cells recognize the bacterial peptide epitopes 
presented by classical MHC class I and II molecules, respectively. [21] Furthermore, non-
classically restricted CD8+ and CD4+ T cells recognize lipid and glycolipid antigens presented 
by CD1 molecules [22]. Recruited T cells travel to the lung tissue and are present in the 
mature granuloma. Their role is crucial for the control of infection after the acute phase. 
After the onset of adaptive immunity, most humans become asymptomatic and are 
considered to have LTBI. [21, 23] 
Approximately 5% of infected subjects rapidly develop progressive disease, active TB. 
Usually, most immunocompetent persons eliminate the invading bacteria or maintain the 
infection in a latent state. These subjects develop an effective adaptive immune response 
and remain free of symptoms. A proportion of these might later develop an active disease, a 
process called disease reactivation. [9, 13] The risk of disease reactivation is significantly 
increased in immune-compromised patients. However, only a few mechanisms explaining 
reactivation in humans have been consistently identified. These are the therapeutic 
neutralization of tumor necrosis factor-α (TNF-α), the quantitative and qualitative loss of 
CD4+ T cells in HIV-infected persons [23], and a deficiency of vitamin D [19]. Other conditions 
and mechanisms associated with reactivation, such as diabetes mellitus, malnutrition, T-cell 
exhaustion and altered antigen expression, have also been suggested, but not thoroughly 
proven. [23] 
1.3.1.2. Immune evasion and the roles of granulomas 
M. tuberculosis uses many immune evasion mechanisms during the innate immunity stage, 
such as the prevention of phagosome-lysosome fusion, the inhibition of host cell apoptosis, 
the neutralization of toxic oxygen and nitrogen intermediates, and the inhibition of IFN-γ 
receptor-mediated signaling [21]. Due to these mechanisms, pathogenic mycobacteria are 
able to resist or evade the host immune response during the innate immunity stage. This 
delayed initiation of adaptive immunity allows uncontrolled growth of bacteria in the lungs 
during the innate immunity stage and leads to the progression of infection. [23] The host-
protective role of the granuloma, the well-organized hallmark structure of tuberculosis, has 
traditionally dominated in the literature. This hypothesis is supported by the observation that 
poorly formed granulomas and hypersusceptibilty to M. tuberculosis occur under TNF-α, IFN-
γ, or IL-12 deficiency. [18] However, it has recently been demonstrated in a zebra fish 
embryo model that the early granuloma benefits the pathogenic mycobacteria.  The ESX-1 
type VII secretion system, encoded by the region of difference 1 (RD1) virulence locus, has 
been shown to promote the recruitment of macrophages to granulomas and drive the 
necrotic death of infected cells. This allows the release of intracellular bacteria and further 
expansion of the bacterial population into newly recruited macrophages. [24] 
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The tuberculous granuloma can be caseous, consisting of an acellular necrotic center with 
surrounded macrophages, neutrophils, DCs, natural killer cells, and B and T lymphocytes 
(Figure 2). Necrotic neutrophilic, fibrotic, and suppurative granulomas also occur. Ghon’s 
complex, with a calcified granuloma in a single lung lobe and associated draining lymph node, 
has been related to LTBI. In this form of a granuloma, successful immune responses with 
fewer inflammatory cells are present. [15, 18, 25] 
 
 
 
 
 
 
Figure 2. Cell organization of a mature tuberculous granuloma. The granuloma is a compact aggregate that is 
formed by linked specialized macrophages, epithelioid cells, and fused multinucleated giant cells. Foam cells are 
located on the edge of the necrotic center and bacteria are present in macrophages and other phagocytic cells, 
but also extracellularly in necrotic areas of the granuloma. The mature granuloma contains many other cell 
types, such as dendritic cells and T and B cells. Reprinted with permission from Nature Publishing Group: Nature 
Reviews Immunology [18], copyright 2014. 
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Recently, in models with cynomolgus macaques, the spectrum of lesions, including Ghon’s 
complexes, was described in animals with active TB. Subclinical TB, in which macaques had 
no clinical symptoms but had positive bronchoalveolar lavage fluid cultures for M. 
tuberculosis, was demonstrated. [26, 27] Most recently, similar bacterial killing capacity in 
individual lesions of active TB and LTBI has been reported. In active TB, high variation in 
sterilizing activity between lesions has been recorded within a single macaque. [28]  
In humans, a range of lesion types found in active TB, with replicating bacteria, have also 
been demonstrated in LTBI using the high-resolution computed tomography (HRCT) analysis 
[29]. On the other hand, a strong evidence for nonreplicating persistence of M. tuberculosis 
during latency has been reported. This study was performed with clinical isolates recovered 
during primary infection and reactivation of the disease in the same persons more than three 
decades later. No sequence variation between the pairs was detected [30]. Because a variety 
of granuloma types are found in active TB, LTBI, and in disease reactivation, the function of 
the granuloma, rather than its structure has been suggested to be essential for the 
determination of the infection stage. [15] 
1.3.2. The cells of the adaptive immune response 
1.3.2.1. CD4+ T cells 
T helper (Th)1 cells. The specific immune response against M. tuberculosis consists of a 
variety of cell types. Best characterized are CD4+ Th1 cells [21]. The development and 
maintenance of Th1 cells is induced by IL-12 [31]. After phagocytosis of M. tuberculosis, 
macrophages and DCs produce IL-12 which induces the effector functions of CD4+ T cells, 
especially the production of IFN-γ. Together with TNF-α, IFN-γ induce the antimycobacterial 
effects of macrophages. In TB, IFN-γ is produced by most infected subjects and its secretion is 
induced by a variety of mycobacterial antigens. However, IFN-γ secretion correlates poorly 
with protection. [21] It has been suggested that CD4+ T cells also have other functions in the 
control of TB, such as the promotion of Fas-L-mediated apoptosis of infected macrophages 
and the secretion of other cytokines, including IL-2 and TNF-α [14]. The high frequencies of 
polyfunctional CD4+ T cells that secrete multiple cytokines have been suggested to correlate 
with protection in chronic virus infections with a low antigen load [32]. Recently, the same 
has also been proposed for TB. In a few studies, higher frequencies of CD4+ T cells producing 
IFN-γ, IL-2, and TNF-α have been recorded in the blood of subjects with LTBI than in that of 
patients with active TB [33, 34]. Whereas, in some other studies polyfunctionality have been 
related to active TB [35, 36].   
Th2 cells. The Th2 pathway assisting humoral immune response is more important for the 
protection against extracellular pathogens. It has a lesser impact against intracellular 
pathogens [37]. Th2 cells produce IL-4, IL-5, and IL-13, and regulate antibody-mediated 
immunity [38]. In TB, Th2 cells have been association with decreased immunity and increased 
immunopathology [38, 39]. Moreover, excess production of IL-4 is related to a depressed Th1 
response [40] and increased disease severity [41]. IL-4δ2, the splice variant and antagonist of 
IL-4, has an opposite role and is related to the control of M. tuberculosis infection [42, 43].  
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Regulatory T cells (Tregs). Inducible Tregs arise in the periphery from conventional CD4+ T 
cells in response to specific stimulatory signals, while natural Tregs develop in the thymus 
after a normal maturation process [44]. A specific marker and unique transcription factor of 
natural Tregs, forkhead box P3 (FoxP3), is required for the generation of these cells. The 
regulatory mechanisms exploited by Tregs suppress the effector functions of T cells, which 
limit immune-mediated tissue pathology but may also result in a failure to control an 
infection. [45] In TB, Tregs delay the priming of adaptive immune cells and their migration to 
the lungs, a phenomenon which allows uncontrolled replication of M. tuberculosis. The 
number of Tregs at the infection site and in the periphery is increased in active TB. That 
positively correlates with the bacterial burden and severity of the disease. However, it is not 
known whether the expansion of Tregs is a cause or a consequence of advanced TB. [44] 
Th17 cells. A recently recognized cell subset, Th17 cells produce effector molecules IL-17, IL-
17F, IL-21, and IL-22, which induce tissue inflammation. Th17 cells are linked to 
autoimmunity, but have also been associated with some bacterial infections, including TB. 
[46] Induced in draining lymph nodes, Th17 cells migrate to the lungs and execute effector 
functions [17]. In mice, this cell subset has been shown to respond rapidly after antigen 
challenge. They help to recruit neutrophils and effector cells, such as IFN-γ-producing cells, 
and that promotes granuloma formation [17, 47]. Whether these cells play a role in the 
protection against or the control of TB is not yet well known. Excessive production of IL-17 
potentially mediates immunopathology and has detrimental effects on the lung tissue. The 
balance between Th1 and Th17 cells during TB is essential in promoting immunity and 
preventing immunopathological consequences. [17] 
Th9 cells. Th9 cells are a recently identified cell population distinct from Th1, Th2, and Th17 
subsets. They have been suggested to participate in inflammation and the development of 
allergic reactions. [48] Th9 cells have also been found in the pleural fluid of patients with TB 
pleurisy [49]. In the same study, constructed with cells isolated from the pleural effusion of 
patients with TB pleurisy, differentiation into the Th9 cell subset from CD4+ T cells was shown 
to be induced by transforming growth factor-β and IL-4   and suppressed by IFN-γ [49]. In 
addition, a positive correlation between Th9 and Th17 cell frequencies and the contribution 
of IL-9 to Th17 differentiation has been reported [49]. The function of Th9 cells in the 
pathophysiology of TB is not yet known. [50] 
1.3.2.2. Cytotoxic CD8+ T cells  
CD8+ T cells contribute to the control of M. tuberculosis infection. They recognize M. 
tuberculosis antigens and produce effector molecules, such as IFN-γ, TNF-α, and IL-2 [34, 51], 
but also lyse infected cells and kill intracellular bacteria via the granule exocytosis pathway 
[52]. A protective role of cytotoxic T lymphocytes (CTLs) has been suggested by human 
studies in which higher frequencies of M. tuberculosis -specific CD8+ T cells producing 
perforin (Prf)- and granzyme B (GrB) were found in the household contacts (HHC) of TB 
patients and healthy vaccinated subjects compared to patients with active TB. In these 
studies, reduced cytotoxic activity in patients with active TB has also been reported. [53, 54] 
In addition, the lytic activity of CD8+ T cells has been found to decrease gradually with 
increasing severity of the disease [55]. Furthermore, increases in the frequency of Antigen 
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85A peptide-specific Prf-producing effector cells have been observed after four months of 
anti-TB treatment [56].   
1.3.2.3. B cells and humoral immune response 
Recently, also B cells and the humoral immune response have been suggested to possess a 
protective role against M. tuberculosis. For example, increased immunopathological 
consequences and susceptibility to M. tuberculosis have been shown in B cell-deficient mice 
[57]. Furthermore, monoclonal antibodies to M. tuberculosis surface components have been 
reported to increase survival times, and reduce disease dissemination and bacterial burden in 
experimentally infected mice [58]. The inhibition of Fcγ receptors, expressed by antigen-
presenting cells, in the lungs of M. tuberculosis-infected mice limited the protection and 
suggests the beneficial role of humoral immunity [59]. In humans, a wide variety of M. 
tuberculosis antigens have been reported to induce the antibody response. BCG vaccination 
has been shown to induce IgG and IgM responses to several antigens, especially LAM. [58] 
LAM-specific IgG antibodies have been demonstrated to assist cell-mediated immunity by 
increasing phagocytosis by neutrophils and antigen processing and presentation by DCs [60]. 
1.4. Vaccination 
The Bacillus Calmette-Guérin (BCG) vaccine contains a live attenuated strain of M. bovis, 
originally isolated from cattle. It was used for the first time in 1921, and following the WHO 
Expanded Program of Immunization in 1974, vaccination coverage rates soon exceeded 80% 
in TB endemic countries. However, BCG vaccination has a limited impact on TB transmission. 
It is only protective against childhood TB meningitis and disseminated TB. [61] In Finland, the 
BCG vaccination program for newborns began in the 1940s and a 98% vaccine coverage was 
subsequently achieved. In many low incidence countries, such as Sweden and Norway, only 
children in risk groups are vaccinated. After careful risk and cost-effectiveness assessments, 
since 2006 the vaccinations have also been targeted at risk groups in Finland. [62] 
1.5. Antibiotic treatment of tuberculosis 
M. tuberculosis is resistant to many common antibiotics [63]. Treatment comprises a 
combination of three or more anti-TB drugs for a period of at least 6 months. The first 
effective antimicrobial agents against clinical TB, streptomycin (SM) and para-amino salt of 
salicylic acid (PAS), were discovered in the 1940s. In the 1950s, 24-month triple therapy with 
isoniatzid (INH), SM and PAS resulted in a cure for 90–95% of patients. Later, ethambutol 
(EMB) replaced para-amino salt of salicylic acid. The first bactericidal antibiotic, rifampicin 
(RMP), was included in the treatment of TB in the 1970s. In the 1980s, a 6-month therapy 
with pyrazinamide (PYR), isoniazid, and rifampicin was found to be effective and is still used 
as the first-line anti-TB treatment. [64, 65] Following the emergence of drug-resistant strains, 
new antibiotic classes, such as fluoroquinolones have been used. The increasing rate of 
resistance necessitates a continuous search for new drug candidates. [66] 
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1.6. Diagnostics of tuberculosis 
The diagnosis of active TB has traditionally been based on clinical and radiological findings, 
acid-fast bacilli (AFB) smear microscopy and M. tuberculosis culture. Since the last decade, 
nucleic acid amplification tests (NAATs) have also been widely used. LTBI can be diagnosed 
with the radiological findings, known history of M. tuberculosis exposure and TST or IGRAs. 
[9, 67, 68] The following sections introduce the conventional and some non-conventional 
methods and host- or pathogen-specific markers (Table 1) investigated during the last 
decades. 
 
 
1.6.1. Conventional methods 
AFB smear microscopy is still the most widely used rapid and inexpensive method for TB 
diagnosis, especially in developing countries [7]. The method is also used to determine the 
contagious level of the infection [127]. However, the sensitivity of smear microscopy varies 
from 20% to 80%, and in other than respiratory samples the diagnostic yield is lower. From 
104 to 106 AFB/ml is usually required for a positive result. The specificity is high, being up to 
94%, in high prevalence areas. [7] Improved sensitivity has been shown with fluorescence 
microscopy with auramine or acridine compared to conventional methods with carbolfuchsin 
[128], and also when a sample volume of more than 5 ml is concentrated by 
cytocentrifugation [129, 130]. In the future, smear microscopy could be improved, for 
example, by using ultra-bright light-emitting diodes (LED) in microscopy [131]. 
Culture is the gold standard for the laboratory confirmation of TB, but it requires 2–6 weeks 
of incubation. Since the 1990s, more rapid and sensitive semi-automated and automated 
culture systems using liquid media instead of Löwenstein-Jensen solid media have been 
developed. At present, systems such as the BACTEC 460TB (Becton Dickinson, NJ, USA), 
BACTEC MGIT 960 (Becton Dickinson) and MB/BacT ALERT 3D (bioMérieux, Craponne, 
France), are widely used. With these methods, in a smear-positive specimen the average 
detection time is 9 to 14 days for M. tuberculosis, and the limits of detection vary between 
10–100 colony-forming units (CFU) per ml. [7] Isolation of bacteria is required for drug-
susceptibility testing and genotyping [9]. Sputum culture and staining have also been used for 
the quantification of mycobacteria and the evaluation of treatment success. Moreover, a 
decline in the CFUs of M. tuberculosis in sputum has been shown to be an objective and 
reproducible method for measuring the early bactericidal activity of anti-TB agents. [132] 
 
 
  
 
 
  
Table 1. Diagnostic markers of TB under research.   
Marker Sample and/or method Associated outcome Reference 
Antigens for immunological assays       
  HBHA protein  PBMCs, IFN-γ concentration LTBI ↑ 69-71 
  DosR proteins  PBMCs, IFN-γ concentration LTBI ↑ 72-76 
  RD peptides and proteins PBMCs, IFN-γ concentration / frequency 
of IFN-γ-producing cells  
Contact with M. tuberculosis↑ 77-79 
Chemokines and cytokines       
  IP-10 Plasma concentration Contact with M. tuberculosis↑ 80-88 
  IL-4/IL-4δ2,   IL-4/IFN-γ mRNA from unstimulated PBMCs Treatment response ↓                 
Infection reactivation ↑ 
41, 89 
Antigen detection       
  LAM Urine concentration Active TB ↑/ treatment response ↓ 90-107 
  Antigen 85 Serum/sputum concentration Active TB ↑/ treatment response ↓ 108-111 
  Rv1681 Urine concentration Active TB ↑ 112, 113 
Molecular methods      
  Transrenal DNA Urine Active TB ↑ 114, 115 
  LAMP Sputum Active TB ↑ 116, 117 
Non-specific markers       
  Volatile organic compounds Breath Active PTB ↑ 118, 119 
  Neopterin Serum concentration Treatment response ↓/ relapse ↑ 120, 121 
  sICAM1 Serum concentration Treatment response ↓  122, 123 
  suPAR Serum concentration Risk of mortality ↑ 123-126 
2
2
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1.6.2. Nucleic acid amplification techniques 
Reliable and rapid direct NAATs became routine, supplemental procedures in many settings, 
during the 1990s [133]. However, the sensitivity of commercial tests ranged from 81.8% to 
100% in smear-positive and from 35.3% to 95.9% in smear-negative respiratory samples 
[134]. A recently evaluated cartridge-based, automated and rapid real-time PCR method, the 
Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), simultaneously detects M. tuberculosis 
and the rpoB mutation related to rifampicin resistance [135]. The method displayed 98.7% 
and 75.0% sensitivity in smear-positive and smear-negative PTB cohorts, respectively, and 
98.4% overall specificity was found. In the same meta-analysis, an rifampicinresistance gene 
was found with 94.1% sensitivity and 97.0% specificity. [136] WHO has endorsed the use of 
Xpert MTB/RIF in diagnostic tests for persons suspected of MDR-TB or HIV-associated TB. 
However, this does not eliminate the need for conventional methods. [137] 
A method developed in the last decade that is highly specific and simple to perform, i.e. the 
loop-mediated isothermal amplification (LAMP) technique using six primer sets, has been 
evaluated [116, 117, 138]. LAMPs have advantages over other NAATs in terms of their low 
cost and simplicity, and they have been introduced as promising platforms, especially for 
resource-poor settings. High specificity and sensitivity in the evaluated LAMPs has been 
shown with smear- and culture-positive samples. However, lower sensitivity has been found 
in smear-negative samples. [116, 117, 138] 
1.6.3. Molecular line probe assays 
The Inno-LiPA Rif.TB (Innogenetics, Zwijndrecht, Belgium), Genotype MTBDR, and Genotype 
MTBDRplus (Hain Lifescience, Gmbh, Germany) line probe assays can be used to detect the 
M. tuberculosis complex and mutations in the rpoB gene. Genotype MTBDR also identifies 
the mutation in the katG gene and Genotype MTBDRplus mutations in the katG and inhA 
genes, both related to isoniatsid resistance. Based on the WHO report with the pooled data 
from systemic reviews and meta-analysis, rpoB mutations can be detected from M. 
tuberculosis isolates with 97% sensitivity and 99% specificity using the Inno-LiPA Rif.TB. 
Moreover, 98.1% sensitivity and 98.7% specificity can be achieved from M. tuberculosis 
isolates using Genotype MTBDR assays, but also from the smear-positive pulmonary samples. 
Isoniatsid resistance can be detected with 90% sensitivity and 99.5% specificity using the 
MTBDRplus assay. [139] 
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1.6.4. Immunological methods 
1.6.4.1. Tuberculin skin test  
In 1890, Dr Robert Koch prepared tuberculin, a glycerol extract of mycobacteria, for the cure 
for tuberculosis. However it caused a febrile reaction in patients.  It was later used for 
diagnosis. In 1907, Dr. Clemens von Pirquet was the first to perform the tuberculin skin 
reaction test (TST) with an intracutaneous injection. Later, Dr. Charles Mantoux modified the 
method. He injected tuberculin with a needle but not with a help of skin incision. Since 
1930s, a sterilized filtrate of M. tuberculosis culture, the purified protein derivative (PPD) has 
been used in the TST. [140] The TST measures a delayed-type hypersensitivity reaction to 
PPD after an intradermal injection [141]. A positive result indicates that a person has an 
immunological memory to mycobacterial antigens. The method does not discriminate 
between active TB and LTBI, and it should not be used for the diagnosis of active TB. [142] 
PPD contains protein components that are shared between all mycobacterial species [143]. 
Hence, exposure to non-tuberculous mycobacteria (NTM) and BCG vaccination reduces the 
specificity of the test. Moreover, the sensitivity of TST is limited, especially in patients with 
advanced TB, HIV-positive individuals, and children [144, 145]. TST requires a return visit for 
test reading to the clinic three days after the injection [141]. Despite many drawbacks, the 
method is still used, particularly in developing countries, probably due to the unavailability of 
accurate and cost-effective methods.  
1.6.4.2. Interferon-γ release assays  
IGRAs are in vitro immune tests based on the detection of antigen-specific T cell immune 
responses. The methods have been introduced as an alternative to TST for the diagnosis of 
LTBI. They have been extensively described during the last decade [146]. Two commercial 
IGRA tests are available. QuantiFERON®-TB Gold In-Tube (QFT-IT) (Qiagen, Germany) 
quantitates released IFN-γ from the supernatant after whole-blood antigen stimulation using 
an enzyme-linked immunosorbent assay (ELISA) [147]. T-SPOT®.TB (Oxford Immunotec Ltd, 
Abingdon, UK) measures the frequencies of antigen-specific IFN-γ-producing cells from a 
purified lymphocyte fraction [148] with an enzyme-linked immune spot assay (ELISPOT) 
(Figure 3). Both assays use the following M. tuberculosis-specific antigens, the early secretory 
antigenic target-6 (ESAT-6), the culture filtrate protein-10 (CFP-10), and TB7.7 (p4) (only in 
QFT-IT), which all are absent in most of the NTMs and BCG strains [141, 149]. This feature is 
advantageous over PPD, especially in populations with a high NTM exposure and general BCG 
vaccination. Neither of the IGRAs can distinguish between active TB and LTBI [146]. 
The TB Network European Trials Group and ECDC have carried out systematic reviews and 
meta-analyses to assess the accuracy of IGRAs in the diagnosis of active TB and LTBI in 
different populations [150, 151]. As concluded in the ECDC guidance, no added value of 
IGRAs combined with standard methods for active TB diagnostics has been found. However, 
in certain clinical situations, including patients with EPTB or negative AFB staining or culture, 
children, or the differential diagnosis of infection with NTM, IGRAs can be used to 
supplement the diagnostic work-up. IGRAs should not be used as a rule-out test of active TB. 
For the diagnosis of LTBI in low-incidence countries, clear advantages over TST have been 
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shown, and IGRAs can be used in contact-tracing algorithms and in risk assessment to 
identify individuals for preventative treatment. A negative IGRA result does not rule out LTBI. 
[146] Only subjects who have an increased risk of developing active TB from LTBI, and would 
benefit from preventative therapy, should be tested by IGRA. [152] 
The estimated sensitivity of IGRAs for the detection of LTBI is 80–90%, when culture-
confirmed TB patients have been tested. In low TB settings, the specificity of over 95% has 
been identified. The reproducibility of the IGRAs is limited and highly susceptible to 
numerous factors related to manufacture, sample processing, analytical testing and 
immunological variability. [152] 
 
 
               
 
 
Figure 3. Immunological principle of IGRAs. A: Antigen-presenting cells recognize and take up invading M. 
tuberculosis bacteria in the lungs. B: Processed M. tuberculosis antigens are presented to naïve T cells in 
lymphatic organs, and they induce the differentiation of naïve T cells into effector T cells. C: M. tuberculosis 
peptides are incubated in vitro with peripheral blood mononuclear cells (PBMCs), including circulating M. 
tuberculosis sensitized effector T lymphocytes and DCs. D: DCs present peptides associated with MHC molecules 
to effector T lymphocytes , and the activated lymphocytes produce IFN-γ, which is measured with ELISA or 
ELISPOT. 
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1.6.4.3. Serodiagnostic tests 
There are numerous commercial serological tests for TB diagnostics. WHO has reviewed 67 
studies for PTB and 25 studies for EPTB in which serological tests have been evaluated. The 
sensitivity and specificity of serological tests have varied from 0% to 100% and from 31% to 
100%, respectively. The tests are not recommended for use in TB diagnostics. [153] 
1.6.4.4. Proposed antigens for immunological assays 
1.6.4.4.1. Heparin-binding hemagglutinin 
Heparin-binding hemagglutinin (HBHA) is a 28-kilodalton (kDa) surface adhesin produced by 
all members of the M. tuberculosis complex, including M. bovis BCG, but not by 
nonpathogenic M. smegmatis [154, 155]. HBHA has hemagglutination and aggregation 
activity and it binds to the sulfated glycoconjugates of non-phagocytic cells, such as those of 
pulmonary epithelial cells [154]. This interaction is mediated by the lysine-rich C-terminal 
region of the protein [156]. It has been demonstrated that HBHA is involved in the 
extrapulmonary dissemination of M. tuberculosis [157]. HBHA has been shown to induce IFN-
γ production and protective immunity in mice, however only when native HBHA (nHBHA), 
that has undergone a post-translational modification, was used in immunization [69]. The 
modified protein contains a complex methylation pattern in the C-terminal domain, which is 
absent from recombinant HBHA, produced in Escherichia coli [69, 155]. A similar methylation 
pattern and immunological properties compared to nHBHA were observed when 
recombinant protein was produced in M. smegmatis (rMS-HBHA) [158-160]. 
rMS-HBHA and nHBHA purified from M. bovis BCG have been used in several studies to 
assess the diagnostic potential of HBHA [70, 71, 159, 160]. In three studies, significantly 
higher concentrations of IFN-γ were found from LTBI subjects compared to the active TB 
group after the nHBHA or rMS-HBHA stimulation of PBMCs [70, 71, 160]. In one study, the 
nHBHA IFN-γ assay was shown to discriminate TST-positive LTBI subjects and active TB 
patients from healthy subjects, half of whom were vaccinated, with a respective sensitivity of 
92% and 55%. A specificity of 94% was observed in both analyses [71]. The same study 
revealed a significant difference between LTBI and active TB groups. However, a high degree 
of overlap was present between LTBI and active TB groups, and the discriminative ability 
between these two groups was not estimated. [71] Comparable IFN-γ levels between persons 
with LTBI and active TB patients who had successfully completed anti-TB treatment was 
reported in one study [160]. 
Only a few of the BCG-vaccinated healthy controls were observed to produce low 
concentrations of IFN-γ after nHBHA stimulation [70, 71]. In a study in which rMS-HBHA was 
used, the BCG-vaccinated control group was not included [160]. 
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When antibody responses to HBHA were examined, the majority of the active TB patients, 
but only a minority of those with LTBI, possessed IgG-class antibodies to nHBHA or rMS-
HBHA. No IgG-class antibodies to nHBHA were found from BCG-vaccinated healthy subjects. 
[70, 159] The presence of rMS-HBHA-specific IgM- and IgG-class antibodies in the serum of 
treated TB patients has been reported in one study [161]. For the diagnostics, future studies 
with larger cohorts are needed.  
1.6.4.4.2. Latency-associated antigens 
Little is known about the mechanisms by which M. tuberculosis survives in granulomas during 
the persistent stage of the infection. The most extensively studied is the oxygen depletion 
model, in which the gradual depletion of oxygen has been shown to lead to the 
nonreplicating persistence of bacteria displaying minimal metabolic, chromosomal and 
structural changes [162]. Besides hypoxia, bacterial respiration has also been shown to be 
inhibited by low levels of nitric oxide and carbon monoxide produced by immune cells [163, 
164]. When M. tuberculosis was cultured under these conditions, the dormancy regulon 
(DosR), including 48 genes, was expressed and the bacteria were prepared for survival in in 
vitro dormancy in a non-replicating form [163, 164]. The DosR regulon has also been 
demonstrated to be crucial for the rapid resuscitation of growth when aerobic and non-nitric-
oxide conditions have been restored [164].  
It has been suggested that the DosR regulon plays a protective role in LTBI. The finding that 
subjects with LTBI, rather than active TB patients, bear specific T cell responses against 
recombinant DosR regulon antigens suggests that the regulon is expressed during latency 
[72]. When the diagnostic potential of DosR antigens was investigated with IFN-γ ELISA, large 
differences were observed in antigen recognition between different geographical 
populations [72-75]. In these studies, most of the recognized antigens in different TST-
positive populations were a probable phosphohexokinase (Rv2029), a hypothetical protein 
(Rv2628), and a possible nitrate/nitrite transporter (Rv1737) [72-74]. Rv2628-specific IFN-γ 
production has also been associated with cured tuberculosis in an Italian study [165]. When 
resuscitation-associated antigen Rv3407 was used for the stimulation of PBMCs of individuals 
of German origin, none of the TB patients but 55% of subjects with LTBI had an IFN-γ 
response in an ELISA assay [76]. Furthermore, different LTBI patients appeared to recognize 
different epitopes of the antigen [76]. Variation in the recognized latency antigens reveals 
that the cumulative IFN-γ response to all known or a few of the most immunogenic antigens 
appears to be the most promising approach for differentiation between LTBI or HHCs and 
active TB [72, 75]. 
Interestingly, IFN-γ levels measured by ELISA after the stimulation of PBMCs with the 
resuscitation proteins Rv0867c and Rv2389c have been found to differ significantly between 
two groups exposed to M. tuberculosis, specifically household and community contacts with 
a positive IGRA result. HHCs with a more intense exposure had a stronger response to these 
antigens. The result suggests that Rv0867c and Rv2389c antigens distinguish different 
exposure levels and might predict future disease progression. [166]  
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1.6.4.4.3. Region of difference 
The M. tuberculosis genome contains 16 regions, called regions of difference (RDs), that are 
lacking or deleted in some strains of M. bovis and M. bovis BCG. Eleven of these 16 RDs of the 
M. tuberculosis strain H37Rv are absent in all the currently used M. bovis BCG vaccine strains. 
[167] The proteins encoded by RDs offer the opportunity to avoid a cross-reaction between 
M. tuberculosis and BCG vaccine-induced immune responses. For example, the RD1-encoded 
ESAT-6, CFP-10, and TB7.7 are used in IGRA tests, as discussed earlier in this thesis [141]. 
The diagnostic ability of six proteins from the RD2 and RD11 regions was tested by IFN-γ 
ELISPOT, and an increase in sensitivity from 86.2% to 92.9% was shown when the IGRA was 
supplemented with a recombinant small subunit of ribonucleotide reductase antigen, 
Rv1981c. However, the analysis of samples from vaccinated healthy subjects revealed a 
decrease in specificity from 100% to 93.3%. [77] In another study, peptides of a putative 
transcriptional regulatory protein from the RD2 region, Rv1985, showed 96.2% sensitivity and 
95.5% specificity when added to the antigen mixture of the QFT-IT assay [78]. These results 
indicate that the accuracy of the currently used IGRAs might be improved in the future with 
new antigens.  
Antibody responses to RD proteins have also been investigated. In one study, IgG antibody 
levels to enoyl-CoA hydratase, Rv0222, from the RD4 region reached the cut-off in 98% and 
90% of TB patients with or without HIV, respectively, and 90% specificity was reported when 
vaccinated healthy subjects were tested [79]. 
1.6.4.4.4. Proteome studies 
Recently, genome-scale proteomic analysis has expanded the possibilities to identify 
antigenic proteins recognized by the antibodies of infected persons. Antibodies to M. 
tuberculosis were measured with high-throughput proteome microarray technology, using 
microarrays that carried 4099 proteins covering more than 99% of the open reading frames 
of M. tuberculosis H37Rv. The results of this study revealed that antibody targets vary 
between active TB patients, but the response is mainly focused on extracellular and 
membrane-associated proteins. [168] In another study involving antibodies to proteins 
encoded by 87% of the open reading frames of M. tuberculosis, 249 antigenic proteins were 
found, including regulatory proteins and proteins related to lipid transport and metabolism. 
When the diagnostic potential of 20 of the most antigenic proteins was assessed with serum 
from 96 active TB patients and 24 healthy controls, the specificity was found to range 
between 92% and 100%. However, sensitivity varied from 14% to 74%. [169] 
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1.6.4.5. Immune cells and their markers 
1.6.4.5.1. IFN-γ-inducible protein  
IFN-γ-inducible protein (IP-10/CXCL-10) is a proinflammatory chemokine induced by IFN-γ 
and produced by antigen-presenting cells infected with microorganisms. The potential of IP-
10 as an alternative or supplemental biomarker to IFN-γ for the diagnosis of TB infection has 
been introduced. [80] Like IFN-γ, IP-10 is produced in vitro in patients with active TB and 
subjects with LTBI, but not in unexposed controls when QFT-IT tubes were used for the 
stimulation [81, 82]. IP-10 is expressed at higher concentrations than IFN-γ [81-83], which 
may enable assay simplification, for example for dried blood or plasma spots [84]. The IP-10 
was found stable in filter papers for at least four weeks, which enables sample delivery over 
long distances [84]. The IP-10 dried plasma spot method derived from QFT-IT tubes was 
evaluated in a cohort including 78 active TB patients and 98 healthy controls [85]. Increased 
sensitivity from 78% to 84%, with a slightly decreased specificity, from 100% to 97%, 
compared to IFN-γ QFT-IT ELISA was found [85]. In the studies with HIV-infected TB patients 
who had low CD4+ T cell counts, slightly increased sensitivity and a lower number of 
indeterminate results were obtained in an IP-10 assay compared to IFN-γ [86, 87]. In children 
under five years old, reduced IFN-γ, but not IP-10 responses to M. tuberculosis antigens were 
found [88]. Contrary to IFN-γ, IP-10 is also expressed at high concentrations by unstimulated 
cells [82]. The variety of methodologies and cut-offs used complicates the interpretation and 
comparison of results [80].  
1.6.4.5.2. Ratios of IL-4 to IL-4δ2 and IL-4 to IFN-γ  
The importance of an IL-4 response to M. tuberculosis was controversial before 2000 due to 
technical issues [170]. IL-4 has a low messenger RNA (mRNA) copy number and it is a labile 
cytokine that is produced in low concentrations. Therefore, it is difficult to detect by 
immunoassays and quantitative reverse transcriptase PCR (RT-qPCR). [171] In earlier studies, 
the methods did not distinguish between IL-4 and IL-4δ2, an alternatively spliced variant and 
antagonist of IL-4 [172, 173]. The later-developed RT-qPCR method has enabled the 
quantification of IL-4 and IL-4δ2 mRNA separately in unstimulated PBMCs [170]. IL-4 is 
expressed in higher quantities by the unstimulated PBMCs of active TB patients compared to 
TST-positive or TB-exposed controls in cohorts from developed countries [89, 174]. In 
contrast, no differences in IL-4 expression have been detected between patients and HHCs 
from a TB-endemic region, where elevated exposure to many pathogens, including 
helminths, is frequent [41]. IL-4δ2 expression is related to LTBI rather than to active TB [175]. 
In the follow-up studies, the ratio between IL-4 and IL-4δ2 mRNAs and also IL-4 and IFN-γ 
mRNAs has been reported to correlate with disease activity and cure. In these studies, the 
expression of IL-4δ2 and IFN-γ decreased relative to IL-4 in TB contacts when they developed 
active TB. During the TB treatment, the expression levels of IL-4δ2 and IFN-γ increased 
relative to IL-4. [41, 89] Variation in the expression levels of IL-4 and IL-4δ2 mRNAs in 
different studies and populations have hampered the use of these genes for diagnostics of 
active TB or LTBI. However, the ratio between expressions of the two genes may be useful in 
monitoring the cure or progression of the disease.   
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1.6.4.5.3. Cytotoxic T lymphocytes  
CTLs are effector T lymphocytes that kill tumor cells or cells infected with intracellular 
pathogens. CTLs destroy their targets by granule exocytosis or by the FAS-ligand pathway. 
Cytotoxic granules contain membrane-disrupting and pore-forming protein, perforin, serine 
proteases, namely granzymes, and the antimicrobial agent granulysin. [52] The killing activity 
of CTLs has been historically measured by chromium (51Cr) release assays and later by 
methods monitoring the release of enzymatic fluorescent dyes [176]. The frequencies of 
antigen-specific CTLs can be measured by tetramer staining. In addition, their ability to 
produce effector molecules can be analyzed by ELISPOT techniques, or by the flow-
cytometric analysis of lysosomal-associated membrane proteins [177, 178]. These 
glycoproteins include CD107a, CD107b, and CD63, which surround the core of the lytic 
granules and are found on the surface of activated, degranulating lymphocytes [178]. mRNA 
expression analysis has also been used for the quantification of up-regulation of cytotoxic 
molecules [53, 179].   
CTLs can be activated in vitro, resulting in the increased expression of cytotoxic molecules, 
such as Prf, GrB, and granulysin, but also in the cytolytic activity when stimulated with a 
variety of mycobacterial antigens, including live M. bovis or M. tuberculosis, or M. 
tuberculosis-specific peptides and recombinant proteins [53-55, 179, 180]. It appears that the 
enumeration of antigen-specific CTLs by methods, such as intracellular staining, is 
complicated, mainly because the cytotoxic effector molecules are expressed constitutively. It 
has also been shown that cells expressing effector molecules were not necessarily able to kill 
their targets. [181] However, antigen-specific GrB and Prf production measured by ELISPOT, 
or the degranulation factor CD107a-expression have been shown to correlate with 
cytotoxicity [177, 178, 182]. 
It has been shown in a mouse model that the cytotoxic potential of CD8+ T cells decreased 
after 20 weeks of infection compared to the early stage of the disease when M. tuberculosis 
was used in an in vitro cell stimulation [183]. In another study with mice, cytolytic activity 
mediated by pulmonary CD8+ T cells was still detectable 37 weeks after the initiation of 
infection when stimulation was performed with CFP-10 peptides [180]. In humans, M. 
tuberculosis-specific CTLs have also been found from HHCs and subjects with LTBI, which may 
suggest a protective role for CTLs [54, 179]. The diagnostic potential of CTLs has not yet been 
extensively studied. 
1.6.4.5.4. Combinations of immunological markers  
Because of the complex pathogenesis of TB, the analysis of only a single immunological 
marker might not be sufficient for the discrimination of active TB from LTBI. When 
multivariate analyses were used to assess the discriminative ability of TB disease stages with 
a combination of multiple immunological markers, high sensitivities and specificities were 
achieved [184-186]. For example, when the concentrations of seven cytokines were 
measured following the in vitro TB10.4 antigen stimulation of whole blood, the combination 
of TNF-α, IL-12(p40) and IL-17 resulted in the 61% sensitivity and 97% specificity for the 
differentiation of active TB patients and HHCs [185]. In another study a total of 45 immune-
related genes were analyzed by RT-qPCR in the ESAT-6-stimulated PBMCs of active TB 
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patients and subjects with LTBI. A combination of IL-8, FoxP3, and IL-12β gene expression 
levels differentiated the tested groups with 97% sensitivity and 89% specificity. [184] When, 
the levels of 17 cytokines or chemokines in the unstimulated plasma samples of active TB 
patients and HHCs were studied using the Luminex assay, the combination of fractalkine, IFN-
γ, IL-4, IP-10, and TNF-α discriminated active TB patients from HHCs, out of whom half were 
IGRA-positive, with 96.7% sensitivity and 100% specificity. [186] 
1.6.4.5.5. High-throughput array techniques 
Recently introduced high-throughput array technologies have enabled the searching of 
broader gene and protein profiles related, for example, to active TB and LTBI. In one study, a 
distinct 393-transcript signature was determined from the blood of active TB patients when 
the genome-wide transcription profile was assessed [187]. This signature pattern was found 
to discriminate between active TB and LTBI with 61.67% sensitivity and 97.75% specificity. 
However, a lower specificity of 86% was recorded when profiles from active TB patients were 
compared to patients with other bacterial or inflammatory diseases. [187] A neutrophil-
driven IFN-inducible gene pattern was found to dominate in patients with the active TBin this 
study [187]. The dominance of the IFN-inducible gene pattern has also been reported in 
another study in which a whole-genome array was used. However, the results of this study 
demonstrated a notable similarity between the gene profiles of patients with active TB and 
sarcoidosis. [188] In a study in which the array technology was used for the identification of 
gene profiles of PPD-stimulated PBMCs, 229 transcripts for active TB were identified. The 
selected genes IP-10, adenolpyrophosphatase-10A, and Toll-like receptor-6 in RT-qPCR 
differentiated active TB from LTBI with 71% sensitivity and 89% specificity [189].  
When the serum protein profiles of TB patients were compared to those of patients with 
sarcoidosis or other destructive pulmonary pathology by the surface-enhanced laser 
desorption ionisation time of flight mass spectrometry method (SELDI-TOF-MS), 95.5% 
sensitivity and 94.9% specificity was recorded. Two out of the 20 most informative peaks 
were identified and found to be serum amyloid A protein and transthyretin. [190] Later, 
active TB patients were compared to subjects with LTBI by the same method, and three peak 
areas overexpressed by active TB patients with 89% sensitivity and 82% specificity were 
observed [191]. 
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1.6.5. Antigen detection 
1.6.5.1. Lipoarabinomannan 
LAM is a 17.5 kDa, highly immunogenic and heterogeneous glycolipid associated with the 
mycobacterial cell wall. It is a virulence factor of M. tuberculosis [192]. Attachment in the 
bacterial cell wall is mediated by a PIMs anchor and extends to around 20 highly branched 
mannose residues that form the core of the LAM. The molecular termini of rapidly growing 
strains comprise linear or branched arabinan motifs. In the virulent species of mycobacteria, 
such as M. tuberculosis and M. bovis, arabinan motifs are extensively capped with mannan 
residues (Figure 4). LAM or related structures are also present in other mycobacterial species 
and other genera of Actinomycotales, such as Corynebacterium. [12, 193] 
 
 
 
Figure 4. Cell-wall-anchored LAMs of M. tuberculosis, M. smegmatis and C. glutamicum. LAM of M. tuberculosis 
is terminated by mannan (green) residues resulting in Man-LAM, while Pi-LAM of M. smegmatis is capped by 
phosphoinositol (blue and gray) and LAM of C. clutamicum by arabinan (pink) units. Reprinted with permission 
from John Wiley and Sons: FEMS Microbiology Reviews [193], copyright 2014. 
 
LAM is released by metabolically active or degrading bacterial cells [192] and it is believed to 
be filtered by the kidney and excreted into the urine (uLAM) of active TB patients [90]. LAM 
as an antigenic marker of TB was first described in the early 1990s, when it was detected in 
the sputum and serum of active TB patients [194, 195]. In 2001, Hamasur reported that mice 
injected with purified LAM excreted it into urine at ng/ml levels when detected by an ELISA 
method with polyclonal anti-LAM antibodies. Detectable levels of uLAM in the 50-fold 
concentrated urine of TB patients but not in that of healthy controls were also found. [91] 
When the method was evaluated with Ethiopian TB patients with positive AFB and healthy 
subjects, with an assay cut-off of 0.45 ng/ml, 81% sensitivity and 90% specificity was 
achieved. When AFB-negative samples were included in the TB group, the sensitivity 
decreased to 74%.  [92] LAM has also been detected in the samples of serum [195, 196], 
cerebrospinal fluid [197], pleural effusion [198] and sputum [93]. However, urine is the most 
extensively studied biological sample and has been suggested as an attractive option for the 
point-of-care diagnostics of active TB. Urine has advantages over sputum, such as safety and 
ease of collection.  
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Two commercial kits for uLAM detection are now available, Clearview® TB ELISA (Alere inc., 
MA, USA) and the lateral flow method Determine TB LAM ag (Alere inc.). Based on 
evaluations performed primarily in Africa and Asia, the accuracy of these tests for clinical use 
is, however, inadequate. In most of the studies the sensitivity of the test in HIV-noninfected 
patients (TB+HIV-) has been found to be lower than 22% [94]. 74% sensitivity has been 
reported in one study [95]. The assay sensitivity is increased in HIV-infected patients 
(TB+HIV+) with a decreased blood CD4+T cell count. Sensitivity up to 85% in patients with CD4+ 
T cell counts <50 cells/µl has been reported. [94] In most of the studies, increased sensitivity 
has been reported in HIV-infected compared to non-infected populations [93, 96-100]. 
According to the manufacturer, these tests are only recommended for use in TB patients with 
HIV co-infection. However, in some studies, no differences in uLAM concentrations between 
TB+HIV+ and TB+HIV- patients have been found [95, 101]. 
The increased assay sensitivity has been explained by immunosuppression due to the loss of 
CD4+ T cells and a further increase in the bacterial burden and uLAM excretion. However, in 
one study, a positive correlation was found between HIV positivity, uLAM excretion, and a 
positive result in the Xpert MTB/RIF assay performed on urine. [99] This result raises a 
question about the relationship between disseminated genitourinary TB and increased uLAM 
assay sensitivity in HIV-infected patients. When the results of the LAM assay were compared 
to smear microscopy in PTB patients, concordant sensitivity, 37%, was only found in TB 
patients with a CD4+ T cell count <200 cells/µl. In TB+HIV- and TB+HIV+ groups with CD4+ T 
cells >200 cells/µl, smear microscopy was more sensitive compared to the uLAM assay. 
However, smear microscopy and uLAM test identified partly different patients.  [93] 
Increased sensitivity of the uLAM assay has been reported in patients with smear-positive 
PTB compared to a smear-negative disease [92, 95-97, 99, 102]. Very low sensitivity in the 
LAM assay was observed in patients with EPTB. [99, 102] 
The concentration of uLAM has varied between studies from pg/ml levels to over 100 ng/ml. 
In these studies, the concentration of urine samples has not been used or no effect on assay 
accuracy has been found.  [95, 103, 104] The kinetics of uLAM excretion is not well 
documented, but in one study in which 32 samples were tested, a positive uLAM result 
converted negative in approximately 50% of the patients between the second and eighth 
week of treatment. In all but one out of the 24 tested, the test was negative after 24 weeks 
of initial of treatment [99]. 
The specificity of commercial uLAM detection tests for active TB varies between 83% and 
100% [90, 94, 105-107]. The cross-reactivity of antibodies used in commercial kits with other 
mycobacterial species or other respiratory pathogens has been investigated with artificial 
samples in which bacterial colonies have been inoculated in broth media [93, 95]. As 
expected, polyclonal antibodies recognized all tested mycobacterial species, but also some 
Nocardia. None of the tested Gram-negative bacteria or bacteria of Staphylococcus or 
Streptococcus families caused a cross-reaction. However, when monoclonal anti-LAM 
antibodies were used, no cross-reaction was observed with some pulmonary pathogens, 
including Nocardia asteroids [199]. When patients with a smear-negative pulmonary NTM 
infection were tested with a commercial LAM test, 12.2% showed a positive result [96]. No 
results have been reported regarding other disease control groups, such as patients with 
pneumonia or urinary tract infection. 
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1.6.5.2. Antigen 85  
The Antigen 85 complex contains three extracellular 30- to 32-kDa secreted proteins, 
mycolyltransferases, that are essential for the M. tuberculosis cell wall biosynthesis [200]. 
Expression of the Antigen 85 complex is induced by the anti-TB drug isoniatsid. This 
mechanism has been suggested to be a response of mycobacteria to compromised cell wall 
integrity [201]. In some studies, the expressed Antigen 85 complex proteins have been 
measured in the sputum of PTB patients as a marker of treatment outcome [108, 109]. 
Significantly higher amounts of Antigen 85 were found in patients with persistent infection 
compared to those who were rapidly cured. In these studies, infection was defined as 
persistent when the BACTEC culture became positive at or after 90 days of anti-TB treatment 
within 20 days of incubation [202]. The difference was only observed in samples collected 3–
7 and 14 days after treatment initiation [109]. These reports, based on a small cohort, 
indicate that parameters measured during the first weeks of therapy may predict the future 
positivity of the BACTEC culture and disease outcome. 
Antigen 85 has also been found in the peripheral blood of active TB patients [110, 111]. 
Bentley-Hibbert measured >30 µU/ml of Antigen 85 with a dot immunobinding assay in the  
sera of all 13 patients tested to have active TB, including patients with smear-negative PTB 
and patients with EPTB. All healthy controls, and also the groups with a positive TST, had 
Antigen 85 concentrations below 30 µU/ml. [110] Later, Antigen 85 was measured in serum 
by ELISA and 96% sensitivity was observed when bacteriologically confirmed TB patients 
were tested. Analysis of the disease control group including patients with acute or chronic 
non-TB diseases, such as asthma or pneumonia, and a healthy control group produced 80% 
and 100% specificity, respectively. [111] When Antigen 85 was measured in urine, lower 
concentrations compared to serum and no correlation with the diagnosis was found. A 
chromatographic analysis of serum showed that Antigen 85 exists in a complex with 
fibronectin or IgG, which may explain its absence in urine. [110] 
1.6.5.3. Rv1681 protein 
To investigate the protein antigens excreted into the urine of PTB patients, liquid 
chromatography and mass spectrometry were used in one study [112]. From approximately 
400 identified peptide sequences, four were found to be identical to M. tuberculosis proteins, 
and one of these, the 32 kDa, putative molybdopterin biosynthesis protein MoeX/MoeA, 
Rv1681, was unique to the M. tuberculosis complex. Importantly, the patients with renal or 
urinary tract abnormalities were excluded from the study, suggesting that the excreted 
protein did not originate from the kidney, but rather from the lungs of the PTB patients. [112] 
Recently, the diagnostic ability of Rv1681 was evaluated [113]. First, recombinant Rv1681 
was expressed and used to produce rabbit antisera. The immunological detection of urinary 
Rv1681 was demonstrated by immunoaffinity purification with produced antisera. When the 
ELISA method with a limit of detection ranging from 20 pg/ml to 50 pg/ml was used, the 
protein was found in 11 of 25 tested non-concentrated urine samples from PTB patients. 
None of the samples from tested TST-positive healthy subjects, patients with urinary tract 
infection, or patients with tropical diseases, such as schistosomiasis, reacted in the test. Also, 
one of the 21 individuals with clinical symptoms consistent with TB, but without bacteriologic 
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confirmation, reacted. The researchers concluded that Rv1681 is an attractive candidate for 
the development of an accurate urine antigen detection method. [113]  
1.6.6. Other methods 
1.6.6.1. Transrenal DNA 
Cell-free nucleic acids, such as those from dying human cells and microorganisms, are 
degraded and released into the circulation [115, 203]. The size of the cell-free nucleic acids in 
the plasma is smaller than 300 bp, which enables DNA fragments to pass through the kidney 
barrier and be excreted into the urine as transrenal DNA [204, 205]. The presence of cell-free 
nucleic acids has been introduced as a disease-activity and stage-differential marker in areas 
such as oncology, organ transplantation, and infectious diseases. The advantage of the 
method compared to other DNA amplifications is that the determination of the infection site 
is not needed. However, the accuracy of the method, and especially the sensitivity of the 
developed clinical applications, is limited. [115, 203] 
In 1997, M. tuberculosis DNA was reported in the culture negative urine of an active TB 
patient [114]. Green reviewed seven papers in which methods for detecting transrenal DNA 
from the urine of TB patients were evaluated. In these studies, the sensitivity of the assays 
varied from 7% to 100%. There is a lack of understanding of the nature of transrenal DNA, 
which has caused inconsistency in the methodology and sample preparation. For example, 
the low copy number and high degradation of urinary DNA and the low molecular weight of 
the fragments complicate sample storage, DNA isolation, and primer design. Because urine is 
an attractive material for TB diagnostics, further studies with optimized and standardized 
methods are needed for the detection of transrenal DNA. [115] 
1.6.6.2. Volatile organic compounds  
Metabolic profiling by gas or liquid chromatography, nucleic magnetic resonance or mass 
spectrometry has increasingly been used in the classification and diagnostics of diseases such 
as cancer and diabetes. In contrast, only a few studies have shown specific metabolic profiles 
occurring in infectious diseases. [206] Organic compounds have been detected in the breath 
and urine of TB patients and have been proposed as diagnostic markers [119, 207]. An 
increased abundance of o-xylene and isopropyl acetate and reduced levels of 3-pentanol, 
dimethylstyrene, and cymol were observed by mass spectrometry in the urine of active TB 
patients compared to controls [207]. Volatile organic compounds were found in the breath of 
TB patients [119] and later described as a point-of-care test detecting derivatives of 
naphthalene, benzene, and alkanes for the diagnosis of active PTB. However, inadequate 
accuracy with 71.2% sensitivity and 72% specificity indicates that further advances are 
required. [118] 
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1.6.6.3. Non-specific immune activation markers 
Some non-specific markers of immune activation have been investigated as markers of active 
PTB, but also as predictors of the TB outcome or treatment response. Neopterin, a pteridine 
derivative of guanosine triphosphate, is produced by monocytes and macrophages upon 
stimulation with IFN-γ. The detection of neopterin concentrations in body fluids provides 
information on Th1-derived immune activation, for instance in viral and intracellular bacterial 
infections. [208] In TB, significantly higher serum and urine neopterin concentrations have 
been reported in patients with active PTB compared to healthy controls [120, 121, 209]. A 
significant decline in serum neopterin levels during treatment was also observed [120, 121]. 
In one study, an association was found between an increased serum neopterin concentration 
after unsuccesfull treatment and bacteriologically confirmed infection relapse [120]. 
Soluble intercellular adhesion molecule 1 (sICAM-1) is an adhesion molecule mainly 
expressed by endothelial cells. It participates in the trafficking of inflammatory cells and is 
up-regulated by TNF-α, IFN-γ, and IL-1 [210]. ICAM-1 has been shown to be necessary for the 
initiation of inflammatory granuloma formation [211]. Significantly higher levels of sICAM-1 
have been found by ELISA in the serum of PTB patients compared to healthy subjects or TB 
patients who had completed 6 months of chemotherapy, and patients with pneumonia or 
lung cancer [122, 123, 212, 213]. sICAM-1 levels also correlated with disease severity and the 
disease extent, and decreased significantly during the first month of anti-TB treatment [123, 
212]. However, in another study, only a modest decrease was found after 13 weeks of 
chemotherapy [123].  
Elevated serum and plasma levels at the time of TB diagnosis and decreases during treatment 
were also described with the soluble urokinase plasminogen activator receptor (suPAR) [123, 
124]. suPAR is involved in the adhesion and migration of monocytes and macrophages. 
Increased levels of suPAR in body fluids have been shown to positively correlate with the 
activation of the immune system [124, 125]. In TB, an association between the number of 
bacteria in sputum and suPAR levels in serum has been described [124]. High suPAR levels 
after one to four months of anti-TB treatment may predict increased mortality [124, 126]. 
  
 37 
 
2. AIMS OF THE STUDY 
 
The aims of this study were to investigate the diagnostic potential of selected biomarkers of 
tuberculosis and to study the specific immune response in different stages of tuberculosis 
infection. The specific aims were as follows: 
 
 To compare the immune responses to HBHA in patients with different stages of TB 
infection and healthy BCG-vaccinated subjects (study I) 
 To improve the performance of Clearview® TB ELISA for the detection of LAM in the 
urine of TB patients without HIV co-infection (study II) 
 To quantify the excreted LAM in urine samples (study II) 
 To investigate the potential of CTLs producing GrB, Prf, and expressing CD107a to 
discriminate the TB infection stages (study III) 
 To examine the phenotypic properties of functional CTLs in the different stages of TB 
(study III) 
 To compare the IFN-γ, IL-4, IL-4δ2, IL-17, and FoxP3 mRNA expression levels in active 
TB and LTBI (study IV) 
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3. MATERIALS AND METHODS 
3.1. Ethical statements 
The study was approved by the ethical committees of the University Hospital of Helsinki 
(232/E5/07, 356/E5/07, 149/2010), the Hospital District of Southwest Finland (47/180/2009), 
the University Hospital of Kuopio (105/2010) and the Medical University Hospital of 
Taichung, Taiwan (DMR-99-IRB-075-2). Written informed consent was obtained from all 
participants. From some of the patients with active TB, who were in isolation, a verbal 
consent was obtained by phone. 
3.2. Study population  
Clinical samples were collected between 2007 and 2013. The patients with active TB and 
NTM infections were from the University Hospitals of Helsinki, Turku and Kuopio, and the 
Medical University Hospital of Taichung. Samples from persons with LTBI and a few of the 
treated persons were provided in collaboration with HUSLAB and rheumatologists from 
Helsinki University Hospital. The persons treated for TB decades ago were recruited and 
interviewed by a medical student, Pekka Tapaninen. Healthy volunteers were laboratory 
personnel and medical students.  
Whole blood, serum and/or urine samples were collected from 62 patients with active PTB, 
16 patients with active EPTB, 30 persons with LTBI, 49 treated for tuberculosis, 5 infected 
with NTM, and 124 healthy subjects. Serum samples were used in study I and urine samples 
in study II. Aliquots of isolated PBMCs were stored in liquid nitrogen and used in studies I, III, 
and IV. The demographic and clinical data are presented in Table 2.  
The diagnosis for the majority of patients with active TB was bacteriologically confirmed by 
M. tuberculosis culture and NAAT. In two pulmonary TB patients, the diagnosis was based on 
clinical and radiological findings, defined according to standard operation procedures, and on 
the response to anti-TB treatment, and in one patient on NAAT only. One patient with TB 
spondylitis was diagnosed with magnetic resonance imaging and a positive IGRA result. 
Samples were taken no later than two weeks after the initiation of anti-TB treatment. 
However, one patient with miliary TB had received anti-TB treatment for three months. From 
one patient with PTB, three urine samples were taken on days 11, 14 and 15, and again nine 
months after treatment initiation.  
The LTBI group consisted of persons with a positive IGRA result, a known history of TB 
exposure, and a lack of clinical signs of active TB. One person was diagnosed with Ghon’s 
complex in the chest X-ray. The decision of the positive IGRA test was based on the standard 
operation procedures adopted in each clinical laboratory. Seventeen out of the 30 subjects in 
the LTBI group had rheumatic diseases and 13/30 had miscellaneous inflammatory 
conditions. Anti-TB treated persons were divided into three groups: seven persons were 
treated with surgery only (Surg.), 32 had been partially treated with anti-TB treatment before 
the rifampicin era (Part.), and 10 had undergone the modern three-drug anti-TB therapy 
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(Mod.). In most of the cases, the sampling was performed decades after the completion of 
treatment. One of the NTM subjects had recently been diagnosed and four of them had been 
treated and were outpatients at the time of sampling. 
Studies in which cell-mediated immunity was tested (I, III, IV) included healthy subjects who 
were BCG-vaccinated (Vaccinated) and IGRA negative. For study II, the BCG vaccination status 
or IGRA result was not defined. In addition, three samples from persons who had not 
received BCG vaccination (Unvaccinated) were included. Samples from healthy subjects used 
in study I were collected anonymously; only data on the approximate age were collected.  
 
 
Table 2. Demographic and clinical data and number of included samples in each study. 
Patient groups n 
Age 
range  
Female    
n (%) 
I   Serum 
/  PBMCs   
II        
Urine 
III    
PBMCs 
IV    
PBMCs 
Active TB, pulmonary (PTB) 62 18 - 86  16 (26)  3 / 4 45 18 22 
Active TB, other organs (EPTB) 16 24 - 89  9 (57)  1 / 2 12 3 3 
  Lymphatic nodes  7 24 - 80 4 (80)  1 / 1 5 2 2 
  Bones 3 32 - 89 3 (100)  - / 1 2 1  - 
  Abdomen 2 26 - 32 1 (50)  - / - 2  -  - 
  Miliary TB 2 81 0 (0)  - / - 2  -  - 
  Parotid gland 1 82 0 (0)  - / - 1  -  - 
  Intestine 1 24 1 (100)  - / -  -  - 1 
LTBI  30 30 - 77 15 (50)  - / - 15 11 20 
  Rheumatic diseases 17 49 - 77 9 (53)  - / - 9 8 13 
  Miscellaneous conditions 13 30 - 69 6 (46)  - / - 6 3 7 
Treated for TB 49 32 - 86 32 (65)  - / - 4 37  - 
  No chemotherapy (Surg.) 7 49 - 82 3 (43)  - / - 1 6  - 
  Partial treatment (Part.) 32 39 - 86 22 (69)  9 / 5  - 23  - 
  Modern treatment (Mod.) 10 32 - 82 7 (70)  - / - 3 8  - 
NTM* 5 66 - 79 4 (80)  - / 4** 1  -  - 
Healthy controls 124 n/a n/a  7 / 16 101 6 8 
*M. avium (n = 3), M. intracellulare (n = 1), M. abscessus (n = 1); **treated; n/a = not available 
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3.3. Sample preparation and storage 
PBMCs were isolated (studies I, III, IV) from whole heparinized blood on a Ficoll Paque 
gradient (Amersham Biosciences AB, Uppsala, Sweden) and stored in the CryoABC Kit 
medium (CTL-Europe, GmbH, Bonn, Germany) in liquid nitrogen until use. Serum and urine 
samples were preserved at -20 °C until use.  
For the ELISPOT assays (study I, III), thawed and washed PBMCs were diluted in the CTL Test 
Medium (CTL-Europe), and for the flow-cytometric (study III) and RT-qPCR assays (study IV), 
in the RPMI cell culture media (Haartbio, Helsinki, Finland/Sigma-Aldrich, Saint Louis, USA ) 
supplemented with 10% heat-inactivated fetal calf serum (Haartbio /Sigma-Aldrich). All 
media used were supplemented with glutamine (2 mM) and penicillin (100 
µg/ml)/streptomycin (0.1 mg/ml) (Sigma-Aldrich). The cells were counted using a blood count 
analyzer (ADVIA-60, Bayer, Germany) (study I) or in Bürker chambers (study II, IV). 
3.4. Antigens 
3.4.1. Recombinant proteins 
Recombinant rMS-HBHA used in study I was expressed in M. smegmatis, and provided by Dr 
Hwa-Jung Kim from Chungham National University, South Korea. The plasmid containing the 
full open reading frame of HBHA was obtained from Dr G. Delogu, University of Sassari, Italy 
[158].  
Recombinant CFP-10 (rCFP-10) and ESAT-6 (rESAT-6) were used in study III. Primers encoding 
the sequence of cfp-10 and esat-6 genes were designed (study III). Purified chromosomal M. 
tuberculosis DNA was used as a template and PCR amplified genes were cloned into the 
pQE30 vector using the QIAexpress System (QIAGEN, GmbH, Germany). The resultant 
plasmids were transformed into E. coli M15 host cells and the transformation mixture was 
plated onto Luria-Bertani plates containing ampicillin and kanamycin. A single colony was 
cultured until growth reached the mid-log phase; optical density at 600 nm was 0.5–0.7. 
Isopropyl-β-thigalactoside was added and after 4 hours of incubation the cells were lysed 
using the QIAexpress System. The lysate was applied to nickel-nitrilotriacetic acid (QIAGEN) 
matrices, washed with isopropanol as described [214] and eluted with urea buffer. The 
molecular weight and purity of the expressed proteins were confirmed by SDS-PAGE gel 
electrophoresis and Western blotting with anti-His antibodies (Clontech Laboratories, CA, 
USA). The protein endotoxin level was determined by the Limulus amebocyte lysate assay 
(GenScriptinc., Piscataway, NY, USA), and was found to be below 0.1 EU/ml. 
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3.4.2. Synthetic peptides 
ESAT-6 and CFP-10 synthetic peptides (study I, III, IV) were from the T-SPOT®-TB kit (Oxford 
Immunotec, Oxford, UK). 
The genomic sequence of the M. tuberculosis H37Rv HBHA protein was used to design the 
15-mer sequential peptides overlapping by nine amino acids (study I). A methyl residue was 
added to three peptides from the C-terminus of the protein and the peptides for serology 
were biotinylated (Proimmune, Oxford, UK; Alta Bioscience, Birmingham, UK). Controls for 
the ELISA method in study I were previously tested peptides [215] from the Borrelia 
burgdorferi VlsE-protein IR6 region (Core Facility of Protein Chemistry, Haartman Institute, 
Helsinki, Finland). 
3.4.3. Extracts 
LAM used in study II was an extract from the M. tuberculosis Aoyama-B strain 
(NacalaiTesque, Inc., Kyoto, Japan).  
PPD used in studies I, III, and IV was obtained from Statens Serum Institute, Denmark. 
3.5. Methods 
3.5.1. Heparin-binding hemagglutinin ELISA (study I) 
IgG- and IgM-class antibodies to rMS-HBHA, synthetic peptides, and PPD were measured by 
in-house ELISAs. The microtiter plates were coated with 100 µl of rHBHA, PPD, or for 
biotinylated peptides with streptavidin, and were incubated overnight at +4 °C. After blocking 
the wells with 0.25% human serum albumin (Finnish Red Cross, Helsinki, Finland) buffer, the 
plates were washed. In the peptide assay, the synthetic peptides were added and the plates 
were incubated for two hours at RT and washed. Serum samples were diluted 1:100 in 0.5% 
human serum albumin-10% fetal calf serum buffer, added in duplicate into plates and 
incubated for two hours. Detection was performed with anti-human IgM or IgG antibodies 
(Jackson Immuno Research, W. Baltimore, USA) diluted 1:5000 in 0.5% human serum 
albumin. After two hours of incubation, 100 µl of 4-nitrophenylphosphate (Boehringer 
Mannheim, Mannheim, Germany) was added as a substrate. The plates were read at 405 nm 
with an iEMS Reader MF (Labsystems, Vantaa, Finland). 
3.5.2. ELISPOT (study I, III) 
T-cell reactivity was tested by an IFN-γ (study I, III), GrB and Prf (study III) ELISPOT assays. A 
total of 2.5 x 105 PBMCs/well were stimulated in duplicate in ELISPOT plates (Mabtech, Nacka 
Strand, Sweden) with rMS-HBHA, HBHA peptides, PPD, and ESAT-6 and CFP-10 peptides 
(study I) or with PPD, or rESAT-6, rCFP-10, or ESAT-6-CFP-10 peptide pools (study III), in the 
CTL Test Media at +37 °C under 5% CO2 for 48 and 22 hours, in respective studies. Cell 
 42 
 
viability was tested by stimulating 5 x 104 cells with phytohemagglutinin. The CTL Test 
Medium was used as a negative control. After the stimulations, the assays were performed 
according to the manufacturer’s instructions (Mabtech). The spots were counted with an 
ELISPOT reader (Biosys-GmbH, Lyngby, Germany) and the readings in media wells were 
subtracted for the calculation of the net values. 
3.5.3. Lipoarabinomannan ELISA (study II) 
Clearview® TB ELISA (Alere Inc., MA, USA) was used to detect uLAM in urine samples. Thawed 
samples were first boiled for 30 min according to the manufacturer's instructions, cooled to 
room temperature, and then centrifuged for 10 minutes at 3000 rpm. Part of the supernatant 
was concentrated 100-fold with Vivapore 10/20 concentrators (Sartorius Ag, Goettingen, 
Germany), allowing the passage of molecules less than 7.5 kDa. Clearview® TB ELISA was 
performed according to the manufacturer’s instructions for concentrated and non-
concentrated samples. A calibration curve was prepared with a commercial LAM 
(NacalaiTesque, Inc.), starting from 20 ng/ml and ending at 0.5 ng/ml. The ODs were read at 
450 nm with an iEMS Reader MF (Labsystems). 
To investigate interfering factors, urine samples from pneumonia patients that tested 
positive (n = 7) or negative (n = 7) in the Binax NOW S. pneumoniae ag test (Alere Inc.) and 45 
samples from patients with urinary tract infection were obtained from the Eastern Finland 
Laboratory Centre Joint Authority Enterprise, Mikkeli, Finland. These samples were obtained 
anonymously. Urinary S. pneumoniae ag positive and negative samples were tested as non-
concentrated and 75-fold concentrated. Urinary tract infection samples were pooled 
according to the characterized bacterial species and tested as non-concentrated and 100-fold 
concentrated. In addition, the urine of a healthy person was spiked with colonies of E. coli, E. 
faecalis, C. albicans and Corynebacterium sp and whole inactivated M. tuberculosis bacteria 
to achieve solutions of 10 to 106 CFU/ml, incubated for one hour at room temperature, and 
processed as actual real samples. 
3.5.4. Flow-cytometric analysis (study III) 
IFN-γ and CD107a were determined from CD4+ and CD8+ T lymphocytes with flow cytometric 
assays, and the phenotypic profile of CD8+CD107a+ T cells was assessed. PBMCs were first 
incubated with PPD or with media alone for 22 hours. Anti-CD107a-FITC (eBioscience, Inc., 
CA, USA) was added to the cells before stimulation. After two hours of incubation, Brefeldin 
A was added (eBioscience). The cells were surface stained with anti-CD8-Horizon-V450 
(Becton Dickinson) and anti-CD4-Alexa Fluor® 700 (Becton Dickinson) and fixed as instructed 
(eBioscience). Anti-IFN-γ-PE-Cy7 (BD) was added with permeabilization buffer (eBioscience) 
for the intracellular staining. For the characterization of surface marker expression, the cells 
were stimulated as mentioned above and surface stained with anti-CD8-Horizon-V450 
(Becton Dickinson), anti-CD45RA-PE-Cy7 (eBioscience), and anti-CCR7-PE (eBioscience). At 
least 105 lymphocytes were analyzed with a FACSAria (Becton Dickinson) flow cytometer and 
the results were processed with the FACSDiva Version 6.1.3 software (Becton Dickinson).  
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3.5.5. RT-qPCR (study IV) 
RT-qPCR was performed for the mRNA expression analyses of IFN-γ, IL-4, IL-4δ2, IL-17, FoxP3, 
and the validated housekeeping gene human ribosomal protein, in the stimulated PBMCs. 
The specific primers [42, 216-219] for the amplification of the selected genes IFN-γ, IL-4, IL-
4δ2, IL-17, FoxP3, and human ribosomal protein were purchased from Sigma Aldrich. The 
sizes of the amplified products were assessed once with gel electrophoresis and later with a 
melting curve analysis. 
PBMCs were incubated with PPD, a pool of CFP-10 and ESAT-6 peptides, and without antigen 
for 22 hours. The cells were lysed with TRI Reagent® (Molecular Research Center, Inc., 
Cincinnati, USA) and mRNA was extracted with the RNeasy mini kit (Qiagen, Dusseldorf, 
Germany). Then, the AMV reverse transcriptase (New England Biolabs, Ipswich, England), 
Oligo(dT)23 primers (Sigma-Aldrich), and dNTP Mix (Thermo Scientific, Waltham, MA) were 
used for the cDNA synthesis. Amplification was performed with a Power SYBR® Green PCR 
Master Mix (Life Technologies Ltd., Paisley, UK). Analysis was conducted with the iCycleriQTM 
Real-time PCR detection system (Biorad, Hercules, CA) and the results were analyzed with the 
comparative Ct method 2ΔΔCt [220]. 
3.5.6. Statistical analyses  
Statistical analyses were performed with GraphPad Prism (versions 4.0 and 6.0, San Diego, 
CA) and the MedCalc software (Ostend, Belgium).  
Correlations between the tested parameters in studies I and III were analyzed by the non-
parametric Spearman’s rank correlation test and statistical differences between the tested 
groups by the non-parametric Kruskal-Wallis test with Dunn's multiple comparison or the 
Mann-Whitney U-test. A p-value of less than 0.05 was considered significant. 
In studies I, II, and IV, sensitivities, specificities, and cut-offs of the assays were calculated 
using the receiver operating characteristic (ROC) curve and area under the curve (AUC). The 
95% confidence intervals were used to assess the discriminative ability of each of the tests. In 
study II, the statistical differences in sensitivity and specificity between the tested methods, 
were analyzed by the Chi-square test and Fisher's exact test. 
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4. RESULTS 
4.1. Ability of the immune response to HBHA to discriminate between the 
stages of TB (study I) 
To investigate the diagnostic potential of HBHA to discriminate between the patients with 
active TB, subjects with treated TB and BCG-vaccinated healthy subjects, IFN-γ-producing 
cells were analyzed using the ELISPOT method in the groups TB, Part., Vaccinated, and NTM. 
In addition, IgG and IgM antibodies were measured in the groups TB, Part., Vaccinated, and 
Unvaccinated. 
4.1.1. Cell-mediated immune response measured by ELISPOT 
rMS-HBHA stimulation induced the production of IFN-γ in all the tested groups, including the  
persons with active TB, with a high level of inter-individual variation in the frequency of cells 
producing the cytokine (Table 3). The mean of the number of the spots in a negative control 
wells was 12. Stimulation with the HBHA peptides did not increase the frequency of IFN-γ-
producing cells compared to the stimulation with media only in any of the tested groups 
(data not shown).  
The frequency of rMS-HBHA-stimulated IFN-γ-producing cells was compared to that of cells 
stimulated with PPD the known T-cell stimulator of M. tuberculosis infected.  A positive 
correlation was found (r = 0.469, p < 0.01) when the samples from all the tested groups were 
included in the analysis.  
As expected, none of the Vaccinated persons responded to the M. tuberculosis-specific ESAT-
6 and CFP-10 peptides, while a response was observed with samples from groups TB and 
Part. (Table 3). To investigate the ability of rMS-HBHA, PPD, CFP-10, and ESAT-6 to distinguish 
between the IFN-γ response primed by M. tuberculosis infection (TB and Part. groups) and 
BCG vaccination, the ROC curves were constructed for the infected (TB and Part.) and 
Vaccinated groups. The respective AUCs with 95% confidence intervals were 0.636 (0.391–
0.886), 0.736 (0.531–0.941), 0.947 (0.842–1.052), and 0.972 (0.917–1.027). The result 
indicated a good discrimination only for the CFP-10 and ESAT-6 assays. As PPD, rMS-HBHA 
showed inability to discriminate TB infection from the immune response induced by BCG 
vaccination. 
Waning of the immunological response to HBHA was studied by dividing the healthy 
vaccinees into two groups according to age. No difference in the frequencies of IFN-γ-
producing cells was found between the groups with approximate mean ages of 25 (n = 7) and 
50 years (n = 8). The result reveals that the immunological memory for HBHA and PPD is 
persistent. 
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Table 3. Frequencies of antigen stimulated IFN-γ-producing cells/106 lymphocytes. 
  
rMS-HBHA  PPD  ESAT-6 peptides CFP-10 peptides 
Group         
(mean age) n 
Median                 
(25th-75th perc.) 
Median                 
(25th-75th perc.) 
 Median                     
(25th-75th perc.) 
Median                     
(25th-75th perc.) 
TB  6 164 (17 - 309) 550 (312 - 745) 99 (71 - 111) 267 (108 - 343) 
Part. 5 21 (11 - 325) 563 (288 - 760) 115 (40 - 229) 160 (96 - 737) 
Vaccinated 15 147 (85 - 340) 274 (151 - 468) 0 (0 - 27)* 14 (0 - 23)* 
  Vaccinated (25) 7 233 (103 - 366) 237 (120 - 459) 4 (0 - 27)** 7 (0 - 21)** 
  Vaccinated (50) 8 123 (67 - 338) 364 (184 - 525) 29 (0 - 39)*** 14 (0 - 25)*** 
NTM  4 84 (36 - 263) 194 (62 - 374) n/d n/d 
*n = 13, **n = 6, ***n = 7, n/d = not defined 
  
 
Also in the semiquantitative analysis of the amount of IFN-γ produced, estimated by the size 
and the intensity of the spots, a high inter-individual variation was observed in all the tested 
groups (data not shown). 
4.1.2. IgG and IgM response  
Specific IgG and IgM antibodies to rMS-HBHA, HBHA synthetic peptides, and PPD were 
measured using an in-house ELISA. IgG-class antibodies to rMS-HBHA were detected in the 
groups TB, Part., and Vaccinated (Table 4). A positive correlation with the IgG response to 
PPD (r = 0.739, p < 0.001) was observed. The result reveals that rMS-HBHA is not usable for 
the discrimination between persons infected with M. tuberculosis and healthy vaccinees. 
Almost all tested persons had IgM antibodies to rMS-HBHA, including one non-vaccinated 
infant. IgM-class antibodies to PPD were not found in the samples of any of the tested 
persons (Table 4).  
 
Table 4. IgG and IgM antibodies to rMS-HBHA and PPD presented 
as optical densities (405 nm). 
  
rMS-HBHA PPD 
Group  n 
Median IgG                     
(25th - 75th perc.) 
Median IgG                   
(25th - 75th perc.) 
TB  4 1.260 (0.346 - 1.806) 0.862 (0.286 - 1.556) 
Part. 9 0.779 (0.657 - 1.255) 0.371 (0.215 - 0.669) 
Vaccinated 4 0.473 (0.329 - 0.668) 0.197 (0.034 - 0.556) 
Unvaccinated 3 0.204 (0.130 - 0.342) 0.024 (0.021 - 0.119) 
Group  n 
Median IgM             
(25th - 75th perc.) 
Median IgM             
(25th - 75th perc.) 
TB  4 1.485 (0.799 - 2.267) 0.077 (0.023 - 0.103) 
Part. 9 0.875 (0.647 - 1.442) 0.071 (0.021 - 0.138) 
Vaccinated 4 1.481 (1.193 - 2.238) 0.032 (0.170 - 0.136) 
Unvaccinated 3 0.449 (0.287 - 1.218) 0.015 (0.040 - 0.026) 
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IgM-class antibodies to three methylated peptides from the C-terminus of the HBHA protein 
out of the 23 peptides tested were found in all tested groups. Samples from two 
unvaccinated infants also had IgM-class antibodies to two methylated peptides. No 
antibodies were found to the other tested peptides. The result may point to a non-specific 
recognition by heterophilic IgM-class antibodies. 
4.2. Lipoarabinomannan detection for the diagnostics of active TB (study II) 
4.2.1. Comparison of the modified and the original method to detect uLAM 
The effect of the 100-fold concentration of urine for the detection of active TB was 
investigated by the Clearview® TB ELISA (Alere Inc.) assay. All samples were analyzed non-
concentrated and 100-fold concentrated. A calibration curve from 20 ng/ml to 0.5 ng/ml was 
run with each test. A statistically significant (p < 0.001) difference between the healthy and 
the PTB groups was detected with both methods. However, a wider dynamic range and 
improved discriminatory power were achieved with the modified method, where the urine 
was 100-fold concentrated (Figure 5A). The cut-off of the modified method was assessed to a 
level of 1.1 ng/ml by the ROC curve analysis. For the unconcentrated sample, this is 
approximately equivalent to 11 pg/ml, if all uLAM is recovered from the processed sample. 
The AUC was calculated and was found to be 0.767, which reveals a moderate discrimination 
between active TB and healthy subjects.  
Figure 5B presents the range of uLAM concentrations in the concentrated samples. In the 
PTB group, a concentration of uLAM up to 17 ng/ml was detected. In intact urine, this 
concentration equals to 170 pg/ml. When the assay was performed as instructed by the 
manufacturer, 2/28 samples from PTB patients gave a positive result, and with the modified 
method the respective figure was 16/28 samples. In the healthy group, 3/101 and 13/101 
false positives were observed in the non-concentrated and modified forms of the test, 
respectively. 
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Figure 5. Detection of uLAM from PTB patients (n = 28) and healthy subjects (n = 101). (A) ODs of non-
concentrated and concentrated samples. (B) Concentration of uLAM in the concentrated samples with the 
calculated cut-off (1.1 ng/ml) presented with a dashed line. Horizontal bars represent the medians of the 
groups. 
 
 
As shown in Table 5, sample concentration improved the assay sensitivity from 7% to 57% (p 
< 0.0001), but decreased the specificity from 97% to 89% (p < 0.05). When the results were 
compared to sputum staining, some (16/24) but not all (12/24) patients were identified by 
uLAM detection.  
 
Table 5. Comparison of LAM detection with sputum staining. 
Method Positive (n) Negative (n) Sensitivity %  Specificity % 
uLAM (as instructed) 2 26 7 97 
uLAM (concentrated urine) 16 12 57 89 
Sputum AFB 24 4 86 n/a 
Sputum AFB + uLAM 
(concentrated urine) 
25 3 90 n/a 
n/a = not available 
     
 
When the modified method was used in the EPTB group, uLAM concentrations in 3/7 
samples reached the cut-off. However, the highest concentration was only 1.4 ng/ml, while in 
the sample of a patient with miliary TB, 16.6 ng/ml of uLAM was found. This sample also gave 
a positive result when analyzed intact. Only one LTBI patient out of 15, and none of the 4 
treated patients were positive after sample concentration. Samples from PTB (n = 17) and 
EPTB (n = 3) patients were also collected in Taiwan, and interestingly, only 2 samples in the 
PTB and none in the EPTB group gave a positive result. The difference was significant (PTB, 
p < 0.05; PTB+EPTB, p < 0.01) when compared to the samples collected in Finland (Savolainen 
et al. unpublished results). The numbers of positive samples when the original and modified 
methods were used are presented in Table 6. 
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Table 6. The number of positive samples using the original 
and modified methods.                
 Group n 
Non-conc. 
n (%) 
100-fold    
n (%) 
TB pulmonary (PTB) 28 2 (7) 16 (57) 
TB of other organs (EPTB)  7 0 (0) 3 (43) 
TB, miliary 2 1 (50) 2 (100) 
TB pulmonary, Taiwan  17 0 (0) 2 (12) 
TB of other organs, Taiwan  3 0 (0) 0 (0) 
LTBI  15 1 (7) 1 (7) 
Treated 4 0 (0) 0 (0) 
Healthy 101 3 (3) 13 (13) 
 
4.2.2. Studies on factors interfering with the specificity of the assay 
In order to examine the interfering factors, urine samples from patients with other infectious 
diseases (groups Urinary tract infection, Urinary S. pneumoniae Ag positive and Urinary S. 
pneumoniae Ag negative) were studied. Altogether, 12/15 samples in the Urinary tract 
infection group gave a false-positive result after sample concentration and 1/15 without 
concentration. However, when the urine from a healthy person was spiked with E. coli, E. 
faecalis and C. albicans in the range of 104 – 106 CFU/ml, no positive results were obtained. 
Corynebacterium sp. produced false-positive results in a dose-dependent manner when 
concentrated. Spiking with M. tuberculosis produced high ODs at low concentrations (10 
CFU/ml). In the Urinary S. pneumoniae Ag positive and Urinary S. pneumoniae Ag negative 
groups, 2/7 and 3/7 of samples produced a false positive result when concentrated, and 0/7 
and 1/7 without concentration, respectively. In a sample from a patient with a pulmonary M. 
avium infection, the concentration just above the cut-off, 1.2 ng/ml of uLAM, was detected in 
a concentrated sample. The results are provided in Table 7.  In conclusion, urine 
concentration increased the number of the samples with a false positive result. The increase 
was most apparent, from 1/15 to 12/15, in the Urinary tract infection group.    
 
Table 7. The number of positive samples in the disease control 
groups.                    
 Group n 
Non-conc. 
n (%) 
100-fold    
n (%) 
M. avium, pulmonary 1 0 (0) 1 (100) 
Urinary tract infection  15* 1 (7) 12 (80) 
Urinary S. pneumoniae Ag pos.     7 0 (0) 2 (29) 
Pneumonia, but  urinary                        
S. pneumoniae Ag neg.  7 1 (14) 3 (43) 
* 45 Urinary tract infection samples pooled according to bacterial 
species. 
 
 49 
 
4.3. Properties and function of cytotoxic T cells in different study groups 
(study III) 
To assess the power of CTLs in differentiating the TB disease stages and to analyze their 
functional properties, GrB, Prf, and IFN-γ ELISPOT and CD107a and IFN-γ flow-cytometric 
analyses were performed for the antigen-stimulated PBMCs in groups TB, LTBI, Surg., Part., 
Mod and Vaccinated. 
4.3.1. Production of granzyme B and perforin by antigen-stimulated cytotoxic T cells 
measured by ELISPOT 
Stimulation with PPD, rCFP-10, rESAT-6, and CFP-10 and ESAT-6 peptide pools increased the 
frequency of effector molecule-producing T cells in all the tested groups (Table 8). In the 
Vaccinated group, M. tuberculosis-specific antigens produced only a minor increase in the 
frequency of antigen-specific cells compared to PPD, as expected. Table 8 shows the 
proportions of GrB-, Prf-, and IFN-γ-producing cells in the tested groups when PPD or rCFP-10 
was used for stimulation. The proportions of rESAT-6-stimulated cells were quite similar to 
those stimulated with rCFP-10 (data not shown). The frequency of Prf-producing cells was 
low compared to GrB- or IFN-γ-producing cells with all tested antigens. In view of the high 
inter-individual variation in the frequencies of GrB-, and Prf-producing cells, and the absence 
of significant differences between the TB and LTBI groups, no added value for the IGRA 
methods in differentiating the TB infection stages was observed. We also found a high 
spontaneous release of GrB (mean, 56 spots/well) and Prf (mean 24 spots/well), which may 
complicate the interpretation of results and the diagnostic use of GrB and Prf ELISPOTs.  
As shown in Table 8, antigen-specific GrB-, Prf, and IFN-γ-producing cells were also found in 
all the treated groups, including the subjects treated with modern three-drug therapy 
(Mod.). Significantly higher frequencies (p < 0.05) of GrB- and IFN-γ-producing cells were 
found in the Mod. group than in the Surg. group. However, the mean age was lower and the 
period from the experienced infection was shorter in the Mod. than in the Part. group.  
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Table 8. Frequencies of GrB-, Prf-, and IFN-γ producing cells/106 PBMCs in the study 
groups. 
    PPD                   PPD                   PPD                   
Group  n 
Median GrB                           
(25th - 75th perc.) 
Median Prf              
(25th - 75th perc.) 
Median IFN-γ              
(25th - 75th perc.) 
TB  17 115 (59 - 359)  23 (0 - 58) 250 (152 - 550)  
LTBI  9 165 (118 - 439) 23 (0 - 89) 183 (68 - 557)  
Surg.  6 101 (0 - 337)  16 (5 - 30) 59 (14 - 121)*  
Part.  23 170 (68 - 261)  26 (0 - 73) 129 (59 - 328)  
Mod.  7 385 (107 - 457)  15 (6 - 64)a 410 (89 - 719)*a  
Vaccinated 6 248 (239 - 341)b 13 (4 - 46)b 220 (22 - 453)  
    rCFP-10   rCFP-10     CFP-10 peptides 
Group n 
Median GrB                  
(25th - 75th perc.) 
Median Prf              
(25th - 75th perc.) 
Median IFN-γ      
(25th - 75th perc.) 
TB  17 58 (0 - 395)  31 (11 -53)c 142 (23 - 267)  
LTBI  9 210 (144 - 434)  15 (0 - 88)d 192 (85 - 397)  
Surg.  6 0 (0 - 320)*  25 (6 - 98)b 24 (0 - 103)  
Part.  23 55 (5 - 111)  8 (0 - 45)e 19 (9 - 108)  
Mod.  7 344 (69 - 648)*f 0 (0 - 0)g 81 (40 - 360)a  
Vaccinated 6 73 (37 - 92)b 0 (0 - 8)g 15 (8 - 41)  
*p < 0.05; an = 5, bn = 4, cn = 13, dn = 7, en = 21, fn = 6, gn = 3 
  
4.3.2. Flow-cytometric analysis of CD107a- and IFN-γ-expressing cells  
The proportions of PPD-stimulated degranulation marker CD107a- and IFN-γ-positive CD4+ 
and CD8+ T cell populations were next analyzed in different subject groups. When all tested 
results (TB n = 13, LTBI n = 5, Surg. n = 5, Part. n = 5, Mod. n = 5 and Vaccinated n = 5) were 
pooled, significantly higher frequencies of antigen-specific CD107a-expressing cells were 
observed in the CD8+ T cell subset (p < 0.01) compared to the CD4+ T cell subset, whereas IFN-
γ was mostly synthesized by CD4+ T cells (p < 0.0001) (Figure 6). The frequencies of CD107a 
and IFN-γ double-positive cells were low in both cell subsets (data not shown). 
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Figure 6. Analysis of IFN-γ- and CD107a-expressing CD8+ and CD4+ T cells. Unstimulated cells were subtracted 
from PPD-stimulated cells and the frequencies of IFN-γ- and CD107a-positive cells were calculated (n = 38). 
Medians of the cell frequencies are shown by horizontal bars. 
 
As shown in Table 9, CD107a-expressing CD8+ T cells and IFN-γ-synthesizing CD4+ T cells were 
found in all the tested groups. No significant differences between the the groups were 
observed.  
 
 
Table 9. Frequencies of antigen-specific CD8+CD107a+ 
and CD4+IFN-γ+ T cells in the study groups.    
    CD8+CD107a+         CD4+IFN-γ+   
 Group n 
Median                        
(25th - 75th perc.) 
Median                                             
(25th - 75th perc.) 
TB 13 0.12 (0 - 0.54)  0.18 (0.08 - 0.27)  
LTBI 5 0.07 (0 - 0.16)  0.21 (0.05 - 0.56)  
Surg. 5 0.11 (0 - 0.83)  0.06 (0.02 - 0.17)  
Part. 5 0.11 (0 - 0.16)  0.15 (0.01 - 0.47)  
Mod. 5 0.07 (0 - 0.29)  0.09 (0.06 - 3.48)  
Vaccinated 5 0.03 (0 - 0.25)  0.11 (0.10 - 1.37)  
 
4.3.3. Correlation between the different markers of cytotoxicity 
A significant positive correlation between GrB and Prf production was only obtained for the 
LTBI group (r = 0.78, p < 0.05). The frequency of CD107a-expressing CD8+ T cells correlated 
positively (r = 0.41, p < 0.05) with the GrB production, but not with the Prf production when 
all the tested samples from different subject groups were included in the analysis. The poor 
correlation between the different cytotoxicity markers might suggest that they are regulated 
independently or are short-lived. 
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4.3.4. Characterization of the surface marker expression of antigen-specific CTLs 
The following classification was used to identify the differentiation stages of antigen-specific 
CD8+CD107a+ T cells: CD45RA+CCR7+ naive (TN,), CD45RA–CCR7+ central memory (TCM), 
CD45RA–CCR7– effector memory (TEM), and CD45RA+CCR7– terminally-differentiated effector 
memory (TEMRA) cells [51]. 
When three samples from each group were analyzed, all cell phenotypes were recorded in all 
the groups. The TEM phenotype was predominantly found in the CD8+ T cell population in the 
groups TB, LTBI, Surg. and Part. TEMRA cells were the most frequent in the Mod. group, and TN 
cells in the Vaccinated group (Table 10). Interestingly, when the percentages of CD107a+ cells 
were analyzed within each cell subpopulation, TCM had the highest proportions of antigen-
specific cells compared to other cell subsets in all the tested groups (Table 11). The results 
may reveal that also TCM cells, which represent the minor cell population in periphery, have a 
role in a rapid recognition of M. tuberculosis and immunologic protection.  
 
Table 10. Cumulative frequencies of each 
phenotype in the test groups when cell subsets 
were analyzed within the CD8+CD107a+ T cell 
pool. 
 
Table 11. Cumulative frequencies of each 
phenotype in the test groups when cell subsets 
were analyzed within each phenotypic 
subpopulation. 
 Group TN TCM TEM TEMRA 
 
 Group TN TCM TEM TEMRA 
TB 0.11 0.01 0.58 0.15 
 
TB 0.61 16.41  6.15  0.17 
LTBI 0.03 0.03 0.10 0.07 
 
LTBI 0.71 9.32  0.66  0.11 
Surg. 0.13 0.19 0.58 0.21 
 
Surg. 0.48 5.32  1.77  0.78 
Part. 0.12 0.25 0.89 0.22 
 
Part. 0.42 8.08  3.05  0.57 
Mod. 0.08 0.05 0.16 0.24 
 
Mod. 0.5 3.67  0.84  0.32 
Vaccinated 0.14 0.04 0.06 0.05 
 
Vaccinated 1.43 5.47  0.29  0.14 
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4.4. Ability of selected immune-related genes to discriminate active TB from 
LTBI (study IV) 
RT-qPCR was employed to analyze the ability of the expression of selected genes, IFN-γ, IL-
17, IL-4, IL-4δ2, and FoxP3 to discriminate the infection stages of TB. The fold increase in 
mRNA expression was analyzed by the comparative CT method (2ΔΔCt), in which expression 
levels were compared with unstimulated samples and with a housekeeping gene, human 
ribosomal protein. 
4.4.1. mRNA expression levels of IFN-γ, IL-17, IL-4, IL-4δ2, and FoxP3 after antigen 
stimulation 
First, the genes were analyzed after PPD stimulation in five samples of the groups TB, LTBI, 
and Vaccinated. IFN-γ, IL-17, IL-4 and FoxP3 mRNA were expressed in the TB and in the LTBI 
group (data not shown). The IL-4δ2 mRNA expression levels were low in both groups. Next, 
M. tuberculosis-specific, CFP-10 and ESAT-6 peptide pool-stimulated IFN-γ, IL-17, IL-4 and 
FoxP3 mRNA expression levels were measured. The peptides stimulated IFN-γ and IL-4, but 
not IL-17 or FoxP3 mRNA expression (data not shown) in the groups TB (n = 11) and LTBI (n = 
6). The respective p-values for peptide stimulated IFN-γ and IL-4, to discriminate between 
active TB and LTBI were 0.983 and 0.199. As expected, the peptide stimulations did not 
increase the expression of any tested genes in the Vaccinated group (n = 4).  
4.4.2. IFN-γ, IL-17 and IL-4 mRNA expression profiles for the differentiation of active TB 
from LTBI  
PPD-stimulated IFN-γ, IL-17, and IL-4 mRNA expressions were chosen for evaluation with 
larger TB (n = 25), LTBI (n = 20), and Vaccinated (n = 8) groups. In this setting, statistically 
significant discrimination between the active TB and LTBI groups was not achieved either 
with a single (Table 12) or with a combination of cytokines (data not shown). 
 
Table 12.  The median 2ΔΔCt and the ability of each cytokine to discriminate between 
active TB and LTBI. 
  TB*                    
Median 2ΔΔCt                      
(25th - 75th perc.) 
LTBI**                  
Median 2ΔΔCt                        
(25th - 75th perc.) 
Vaccinated***                   
Median 2ΔΔCt                        
(25th - 75th perc.) 
p-values 
IFN-γ 22.6 (7.3 - 59.7) 12.1 (6.5 - 25.2) 11.1 (2.2 - 45.8) 0.263 
IL-17 10.6 (3.3 - 30.0) 8.6 (4.6 - 15.7) 5.4 (1.4 - 13.0) 0.698 
IL-4 4.6 (1.5 - 8.3) 2.1 (0.3 - 4.0) 1.7 (1.2 - 4.2) 0.064 
*n = 25; **n = 20; ***n = 8    
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5. DISCUSSION 
A biomarker is an objectively defined indicator that describes the phases of normal or 
pathogenic processes, or pharmacological responses to a treatment intervention [221]. In the 
case of tuberculosis infection, this could mean host- or pathogen-specific markers for 
predicting the reactivation of infection or infection relapse, or to monitor response to 
treatment or elimination of the microbe from the body. [222] There is a particular need for 
markers that would enable us to assess, with just one measurement, whether the person in 
question has active TB, LTBI, or neither. At the moment, the greatest need globally is for 
rapid and affordable point-of-care tests for diagnosing active TB. One solution for this could 
be a non-invasive urine antigen test. [222] On the other hand, there is also a need for 
markers that could be used to distinguish active TB from LTBI in situations where the patient 
exhibits clinical symptoms compatible with active TB, possible pulmonary lesions, signs of 
inflammation and a positive IGRA result, but with no microbiological confirmation. Methods 
suited for predicting reactivation or assessing the need for preventive treatment are also 
lacking at the moment [67]. In cases such as these, with a low bacterial burden, potential 
markers could include a single host-specific markers, as well as combinations of several host-
specific markers. Markers are also needed for monitoring a response to treatment. [67] In 
the event of large, rapid changes in bacterial load, such as in the initial stages of treatment, 
pathogen-specific markers, such as LAM and transrenal DNA, could be appropriate. 
Computed tomography, magnetic resonance imaging [223] and other imaging modalities are 
also needed to lend support to the exploitation pathogen- and host-specific markers in 
diagnosing TB. 
Poor characteriztion of the patient groups studied and the likelihood of heterogeneity within 
groups is a weakness in the literature focusing on the search for new diagnostic biomarkers. 
As a rule, active TB is diagnosed based on bacteriological findings while LTBI is determined 
based on TST or IGRA positivity and the known history of TB exposure. It is likely that both 
groups, active TB and LTBI, comprise many different substages of infection, with differences 
such as the bacterial load, the number, type and location of granulomas, and the 
immunological response. In this thesis, the LTBI group comprised of persons who inflicts 
difficulties in terms of differential diagnosis between active TB and LTBI, i.e., persons who 
have some underlying disease, such as rheumatoid diseases or other miscellaneous 
inflammatory condition. Another feature that makes the population we have studied here 
unique is that we enrolled subjects who had been infected decades ago and had most likely 
not been exposed to tuberculosis since then, due to the low incidence of TB in Finland. The 
quite small groups of tested patients with heterogeneity in age and disease activity, and the 
use of the frozen PBMCs were the limitations of this study. The presence of patients with 
inflammatory diseases undergoing immunosuppressive treatment also hampered the 
interpretation of the results in the immunological studies.  
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5.1. Diagnostic uses of the HBHA antigen in the BCG-vaccinated population 
Heparin-binding hemagglutinin (HBHA), is involved in the adhesion of M. tuberculosis 
bacteria to non-phagocytic cells, such as epithelial cells, thus contributing to the spread of 
tuberculosis outside the lungs [224]. Individuals with LTBI and those treated for TB have been 
shown to have a significantly higher HBHA-specific IFN-γ-response compared to patients with 
active TB [69-71, 160]. The HBHA antigen has therefore been considered as a potential tool 
for differentiating between active TB and LTBI. Even though statistically significant 
differences have been found between the groups, some patients with active TB have been 
shown to have a high IFN-γ-response to nHBHA or rMS-HBHA [71, 160]. In this thesis (study 
I), in addition to persons who had previously undergone treatment, some of the patients with 
active TB were also found to have rMS-HBHA-specific IFN-γ-producing cells in their peripheral 
circulation. It thus seems unlikely that the HBHA-specific IFN-γ production alone could permit 
sufficient differentiation between the active TB and LTBI for diagnostic purposes. 
It has previously been shown that healthy BCG-vaccinated and unvaccinated persons do not 
exhibit IFN-γ response to nHBHA [69-71]. However, a recent study showed that BCG vaccine 
elicited an extensive cytokine response, including IFN-γ to nHBHA in PBMCs [225]. The same 
study also demonstrated that vaccinated adults had an IFN-γ response to nHBHA and that it 
does not wane over time [225]. In this thesis, rMS-HBHA-specific IFN-γ-producing cells were 
found in the peripheral circulation of healthy BCG-vaccinated persons as well (study I). In 
addition, the number of rMS-HBHA-specific cells was found to have a positive correlation (r = 
0.469, p < 0.01) with the number of PPD-specific cells. It thus appears that, similarly to PPD, 
the stimulation of PBMCs with rMS-HBHA does not distinguish the response elicited by the 
vaccine from that prompted by infection. One reason for the differences between the 
findings here and those reported previously may be that the vaccine strains used differ in 
their immune properties. The response to the vaccine may also be influenced by differences 
in vaccination schedules and vaccine manufacturing processeses.  [61] The results of this 
thesis suggest that the possibilities of using HBHA as an antigen for distinguishing between 
the persons infected with M. tuberculosis and the healthy ones with BCG vaccination are 
limited in countries with a widespread vaccination programme.  
There are few studies looking at the possibilities of using HBHA to monitor the TB treatment 
efficacy or TB reactivation. However, Masungi et al. have shown that the HBHA-specific IFN-γ 
response is increased significantly in patients with active TB during the first four weeks of 
treatment [70]. In a recently published study, changes in IFN-γ response to HBHA and ESAT-6 
in persons with LTBI were followed up to 10 years [226]. The investigators summarised their 
findings as follows: a continuous, proportionally higher IFN-γ response to nHBHA, as 
compared to ESAT-6, might indicate a response that protects against active TB. In addition, a 
link between a continuously changing HBHA-ESAT-6 ratio, re-exposure to the pathogen, and 
reactivation of the disease has been described. [226] It is therefore possible that the nHBHA 
antigen could be utilised in the diagnosis of disease reactivation or monitoring of cure. 
Further studies on the subject are needed, however.  
There are controversies between different studies concerning the disease stage-
discriminating ability of HBHA. One reason for this may be the fact that posttranslationally 
modified, complex C-terminal methylation has been shown to be significant for T cell 
recognition and the generation of the IFN-γ response [69]. Even though the methylated 
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structures of HBHA isolated from the M. bovis BCG strain and produced in the M. smegmatis 
strain as a recombinant protein have been shown to be nearly identical, it is possible that 
there are differences in protein folding, and therefore also in immunological recognition. The 
fact that the IFN-γ response was measured in this study (study I) as frequencies of reactive 
cells while most results presented in the literature were based on the quantitative 
measurement of excreted IFN-γ may also partly contribute to the difference. 
5.2. Lipoarabinomannan as a diagnostic marker for tuberculosis 
Properties, such as non-invasiveness, robustness and inexpensiveness of urine antigen 
detection, and the moderate sensitivity and specificity of some tests currently in use, such as 
BinaxNOW® Legionella pneumoniae (Alere inc.) and BinaxNOW® Streptococcus pneumoniae 
(Alere inc.), are the basis for considering the use of antigen tests in the TB diagnostics as well. 
LAM, a heat-stabile glycolipid, forming part of the cell wall of M. tuberculosis, is excreted into 
urine and considered a potential candidate for the development of an antigen test. [227] 
 
The sensitivity of the existing urine LAM tests, Clearview® TB ELISA (Alere inc.) and Determine 
TB (Alere inc.), has been reported to vary between 13% and 93% and the specificity between 
87% and 99% [90, 94, 105]. In addition, higher clinical sensitivities reported are almost 
without an exception linked to the co-infection of HIV and TB and to a decreased frequency 
of CD4+ T cells caused by HIV and the expected higher bacteria load in the body [93, 96-100]. 
In the second study of this thesis, the presence of LAM was demonstrated with the 
Clearview® TB ELISA in the 100-fold concentrated and unconcentrated urine samples from 
TB+HIV- patients and healthy controls. Concentrating the urine increased the sensitivity of the 
method from 7% to 57% (p < 0.0001) while the specificity decreased from 97% to 89% (p < 
0.05). Based on the results, it can be noted that concentrating the urine is necessary to 
obtain even moderate sensitivity in TB+HIV- patients.  
 
Besides the patients with HIV infection, higher sensitivity values with uLAM assays have also 
been linked to TB patients with a more severe disease [102]. Furthermore, uLAM tests 
showed higher sensitivity in PTB patients with a positive sputum smear compared to PTB 
patients with a negative smear [92, 95-97, 99, 102]. High uLAM levels were found in a sample 
of a patient with miliary TB in the present study as well (study II). The concentrated urine 
sample of one out of the four PTB patients with a negative sputum smear was positive for 
uLAM (Table 5). Therefore, the uLAM test and sputum smear could be used as 
complementary methods. In line with earlier findings [99], lower uLAM levels were found in 
patients with EPTB compared to those with PTB (Table 6). Furthermore, in LTBI group, uLAM 
level above the limit of detection were found only in one sample (7%) (Table 6). Based on the 
earlier and our findings, it seems that when the bacterial load in the body increases, the 
amount of uLAM increases as well. However, the previously demonstrated correlation 
between uLAM and M. tuberculosis DNA determined with the Xpert MTB/RIF method [99] 
raises a question whether the positive uLAM is a result of genitourinary TB infection or uLAM 
excreted via kidneys.  
 
The results of this study show that in TB+HIV- patients uLAM is excreted at pg/ml levels. 
Previous studies, most of which have included HIV+ patients, have reported varying levels, 
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even up to hundreds of nanograms per millilitre [92, 95, 103, 104]. It is likely that the 
generally observed poor sensitivity of LAM tests is at least partly associated with the poor 
test performance. However, other factors, such as those related to immunological 
mechanisms cannot be excluded. For example, it has been speculated that if LAM is bound to 
the anti-LAM antibodies, the high molecular weight of the formed immune complexes cannot 
pass through the glomerular membrane and therefore LAM is not excreted into the urine. 
[99]. The speculation was supported by the results indicating that the sera of TB patients 
contain anti-LAM antibodies [228]. In addition, increased levels of immune complexes 
consisting of M. tuberculosis glycolipid antigens and antibodies have been detected in the 
circulation of TB patients [229].  
 
In this study, the number of false positives was shown to be high in patients with urinary 
tract infection. In accordance with earlier studies [93, 95], common bacteria that cause 
urinary tract infections, such as E. coli, were not observed to react in the test when using a 
spiked sample. This allows speculation as to whether the lack of specificity might be 
associated with the inflammatory process itself. This hypothesis requires further research, 
however. The polyclonal antibodies used in the method were shown to recognise the 
bacteria in the family of Corynebacterium, which may be occasionally present as a part of the 
microbiota on mucous membranes. This may partly explain the false positive findings in 
healthy subjects. When developing potential new methods in the future, it is likely that the 
specificity of the method can be improved considerably by using monoclonal antibodies.  
5.3. T cell memory  
Functional CTLs are important for the protection against active TB. For example, higher 
numbers of CTLs producing GrB and Prf have been detected in persons with LTBI and those 
vaccinated with BCG compared to patients with active TB [53, 54]. It has been observed that 
the lytic activity of CTLs is decreased in patients with active TB [55]. On the other hand, it has 
also been suggested that the decreased frequencies of CTLs in the peripheral circulation is 
partly due to the cell compartmentalisation to inflamed tissues [56]. The third study in this 
thesis looked at the possibility of utilising antigen-specific functional GrB-, Prf-, or CD107a-
synthesizing CTLs to differentiate between the stages of TB infection. However, we observed 
that both the patients with active TB and the persons with LTBI have in their peripheral 
circulation cell types with similar surface marker expression profiles and functional 
properties. These include the frequencies of the antigen-specific GrB and Prf-producing 
PBMCs (Table 8) and CD107a-degranulatioin factor-expressing TN, TCM, TEM and TEMRA cell 
subsets (Table 10). In addition, in line with previously published studies [181, 230], we 
observed that the production and release of cytolytic molecules is a dynamic process that is 
difficult to demonstrate repeatedly. In light of these results, a diagnostic approach based on 
the enumeration of GrB-, Prf-, or CD107a-producing CTLs does not appear promising.  
Our results indicate that persons whose active TB was treated decades ago have functional 
CTLs in their peripheral blood in frequencies similar to those of subjects with active disease 
(Table 8). Furthermore, the CTLs of these persons were shown to represent mostly the short-
lived effector-memory cells, TEM and TEMRA (Table 10). Using the same clinical material it was 
previously shown that IFN-γ-producing CD4+ T cells also had the TEM phenotype [231]. What 
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maintains the short-lived TEM cell population in the periphery of treated patients remains 
unclear. Therefore, there is a possibility that even the modern anti-tuberculosis treatment 
does not eradicate the bacteria, which then could lead to the continuous stimulation and 
proliferation of antigen-specific T cell populations. On the other hand, the possibility of 
unspecific stimulation caused by other microbes with similar structures to those of M. 
tuberculosis cannot be excluded, either. It does, however, seem clear that once formed, the T 
cell memory that recognises M. tuberculosis antigens is sustained throughout life, albeit with 
some variation between individuals. This makes the differential T cell-based immunological 
diagnosis of stages of the TB infection difficult. In light of these findings, the suggestion put 
forth in the literature, to exploit the attenuation of IFN-γ response for the detection of 
treatment efficiency, is questionable. Even if the reversion of the IGRA result from positive to 
negative could be observed, the correlation with a stage of the disease is at present very 
unclear [152]. 
One third of the global population is infected with M. tuberculosis when the positive 
tuberculin skin test result is used as a criterion. However, the majority of the infected do not 
develop active TB during their lifetime. Nevertheless, the risk of reactivation is increased by a 
compromised immune defence, for example, when TNF-α blockers are used to treat various 
inflammatory disorders, or when CD4+ T cell levels are reduced, e.g. due to the HIV infection. 
It was recently shown, in a review comprising 18 prospective cohort studies with 19,886 
subjects, that the persons with LTBI diagnosed by TST, have a 79-percent lower risk of 
developing active tuberculosis as a result of being re-exposed to M. tuberculosis, as 
compared to healthy TST-negative persons [232]. This finding has caused speculation as to 
whether having LTBI or post-treatment “immunological scar” might have a protective effect 
against clinical disease.  
The so-called “hygiene hypothesis" has been put forward to explain the growing rate of 
allergic conditions in the Western populations. This theory explains why the immune system 
needs to be primed in infants to shift their immune response from the predominance of the 
Th2 to the Th1 arm, which is required e.g. for the differentiation of Tregs.  The factors 
responsible for this priming are not yet fully understood. However, the contact with bacteria 
belonging to the Enterobacteriacae family seems important. [233, 234] Early contact with 
mycobacterial antigens, even as LTBI or after vaccination, may be beneficial too. Thus, for 
example, a significant decrease in the prevalence of recent allergic rhinitis in the TST-positive 
children compared to the TST-negative ones was reported [235]. On the other hand, the 
systematic review of the literature showed a high variation in the results between studies, in 
which the correlation between M. tuberculosis infection or BCG vaccination and atopic 
diseases in children have been studied [236]. That is explained, e.g., by the variation in the 
BCG  vaccination schemes,  vaccine strain differences, differences in exposure to 
environmental mycobacteria and the lack of uniformity in the definition of atopy [236]. The 
benefits of latent infections to confer protection against more detrimental infections were 
also described in animal models. It has been recently shown in mice that the IFN-γ-mediated 
macrophage activation maintained by latent Epstein-Barr virus or cytomegalovirus infections 
has a protective role against some bacterial infections [237]. 
 59 
 
5.4. IFN-γ, IL-17 and IL-4 mRNA expression in the differential diagnosis of M. 
tuberculosis infection stages 
It is possible that high-throughput array techniques are needed in order to find markers that 
distinguish the stages of TB infection [190]. Therefore, the development of robust diagnostic 
methods for the diagnostics of active TB calls for multiplex method formats, in which 
multiple markers can be detected cost-effectively in a single reaction [186].  
The calculation of the combined expression, of IFN-γ, IL-17 and IL-4  mRNAs is justified on the 
basis of the following: a) when the immune response is evolved after the contact with the 
pathogen, CD4+ T lymphocytes differentiate into distinct major lineages, Th1, Th17 or Th2, 
each expressing IFN-γ, IL-17 or IL-4, respectively; b) because the different cell lineages, Th1, 
Th17 and Th2, co-operate or interfere with each other during the inflammatory process, the 
dominant subset may differ. [38] Therefore, the combined analysis of cytokines produced by 
these cell subsets takes into account any shifts that might occur.  
In this thesis, no statistically significant differences in IFN-γ, IL-17 and IL-4 mRNA expressions 
were found in patients with active TB and LTBI. However, a trend towards discrimination was 
shown.  The method may prove useful if repeated on a larger sample size when more 
meticulously selected LTBI patients with a homogenous clinical background are enrolled 
We observed that, compared to CFP-10 and ESAT-6 peptides (p = 0.983), PPD (p = 0.263) 
stimulation had a higher capacity to discriminate the active TB group from the LTBI group 
when IFN-γ was measured. As reported, PPD stimulation has resulted in the higher IFN-γ and 
IL-17 cytokine production compared to the stimulation with CFP-10 and ESAT-6 peptides 
[185, 238]. By definition, patients with active TB have a higher bacterial load, stronger 
inflammatory reaction and quantitative and qualitative differences in reactive T-cell pools 
compared to LTBI. Therefore, recognition by the CD4+ T cells of TB patients of a higher variety 
of protein components of the PPD rather than CFP-10 and ESAT-6 peptides alone offers a 
distinct diagnostic advantage.  
Earlier, significantly higher FoxP3 mRNA levels have been demonstrated in antigen-
stimulated PBMCs of patients with active TB than in subjects with LTBI [184]. In this thesis 
study, no difference in FoxP3 mRNA levels was observed between these groups. FoxP3 mRNA 
is expressed low levels [184], and its expression might peak earlier than at 22 h, the time 
point used in this study. Consistently with earlier findings [89], antigen stimulation did not 
induce the expression of IL-4δ2 mRNA in this study. 
Importantly, in other studies reporting the high discriminative ability of a variety of gene 
expression profiles, the LTBI group has consisted of healthy subjects, mainly household 
contacts [184, 189]. By contrast, our LTBI cohort consisted of patients with underlying 
diseases, such as rheumatic diseases or other inflammatory disorders. Similarly to active TB, 
these patients have disease manifestations compatible with active TB. Our LTBI patient group 
had dysbalanced cytokine production, and in the real clinical situation this LTBI cohort is 
therefore a challenge. To our knowledge, such an approach of enrolling an LTBI group with 
clear disease manifestations has not previously been attempted. 
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6. CONCLUSIONS AND FUTURE PROSPECTS 
The urine LAM tests that are currently in use are not suitable as point-of-care test for the 
diagnostics of active TB in TB+HIV+ or TB+HIV- patients. In this study, the sensitivity of the 
Clearview® TB ELISA method could be significantly improved by concentrating urine 100-fold. 
However, because only moderate sensitivity (57%) and specificity (89%) was achieved, the 
method is still inadequate for the diagnostic use. Compared to protein antigens, the 
glycolipid could be a preferred antigen for TB diagnostics, for example, due to its heat 
stability. This is an important aspect, because the infectivity of a urine can be reduced by 
heating. Furthermore, a urine sample of patients without genitourinary TB infection is 
presumably much less infectious than a sputum sample. It is obvious that many issues, such 
as those related to kinetics of the antigen excretion in active TB, call for further studies. In 
addition, in order to improve the specificity of the method, it is very likely that, in the future, 
the use of monoclonal antibodies and careful analysis of preanalytic factors will be necessary. 
The most fascinating results of the current thesis include the finding that the memory of 
CTLs, generated by a previously treated active TB, is sustained for several decades, despite 
adequate treatment with bactericidal rifampicin. It is possible that long-lived T-cell memory 
may provide some protection against re-infection with mycobacteria, or even against other 
detrimental infections.  As shown in this thesis, because of T-cell memory, assays based on 
host-related biomarkers are less useful for measuring treatment efficiency.  
Based on the results, the ability of PPD-stimulated IFN-γ, IL-17 and IL-4 mRNA expression in 
PBMCs to discriminate the disease stage was not sufficient for diagnostic use. However, 
larger sample cohorts should be tested. Furthermore, the LTBI group should be more 
homogeneous in terms of clinical manifestations, the duration of the clinical course, and the 
duration and assortment of anti-rheumatic drugs, because each of these factors affects the 
basal level of cytokine production. It could be possible that by using a combination of several 
biomarkers, active TB could be distinguished from LTBI immunologically. New 
immunodiagnostic tests could provide a possibility for detecting the reactivation of TB 
infection, thus leading to earlier preventive treatment than by using microbiological or 
molecular methods. The search for new immunological markers should therefore continue. In 
our opinion, however, the search for biomarkers of tuberculosis infection should be more 
focused on pathogen-related than on host-related markers, because these offer a higher 
degree of specificity. 
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